Designation	Ref.	Download
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS	J Prev Alz Dis 2015;2(4):269-396	38434
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS	J Prev Alz Dis 2016;4:262-379	18547
THE ALZHEIMER’S PREVENTION CLINIC AT WEILL CORNELL MEDICAL COLLEGE / NEW YORK - PRESBYTERIAN HOSPITAL: RISK STRATIFICATION AND PERSONALIZED EARLY INTERVENTION	J Prev Alz Dis 2015;2(4):254-266	7754
ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE	J Prev Alz Dis 2015;2(2):128-135	7339
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK	J Prev Alz Dis 2016;3(2):114-120	6079
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020	J Prev Alz Dis 2020;7(S1):S55-S119	5422
CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL	J Prev Alz Dis 2017;4(3):149-156	5403
VITAMIN D AND DEMENTIA	J Prev Alz Dis 2016;3(1):43-52	4955
A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS)	J Prev Alz Dis 2015;2(4):227-241	4894
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”	J Prev Alz Dis 2016;3(4):219-228	4386
A PERSONALIZED 12-WEEK “BRAIN FITNESS PROGRAM” FOR IMPROVING COGNITIVE FUNCTION AND INCREASING THE VOLUME OF HIPPOCAMPUS IN ELDERLY WITH MILD COGNITIVE IMPAIRMENT	J Prev Alz Dis 2016;3(3):133-137	3793
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER’S DISEASE AND OTHER TAUOPATHIES	J Prev Alz Dis 2017;4(4):236-241	3501
REVERSIBLE AND SPECIES-SPECIFIC DEPIGMENTATION EFFECTS OF AZD3293, A BACE INHIBITOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE, ARE RELATED TO BACE2 INHIBITION AND CONFINED TO EPIDERMIS AND HAIR	J Prev Alz Dis 2016;3(4):202-218	3070
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2017;4(2):109-115	2976
BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER’S DISEASE	J Prev Alz Dis 2016;3(1):30-42	2896
COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMER’S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER	J Prev Alz Dis 2016;3(3):164-172	2790
ETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER’S DISEASE RESEARCH	J Prev Alz Dis 2017;4(2):125-131	2621
CLINICAL AND ECONOMIC CHARACTERISTICS OF MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: TRANSFORMING FUNCTIONAL SCORES INTO LEVELS OF DEPENDENCE	J Prev Alz Dis 2015;2(2):115-120	2564
NEFLAMAPIMOD: CLINICAL PHASE 2B-READY ORAL SMALL MOLECULE INHIBITOR OF P38? TO REVERSE SYNAPTIC DYSFUNCTION IN EARLY ALZHEIMER’S DISEASE	J Prev Alz Dis 2017;4(4):273-278	2532
BRIDGING THE TRANSLATION GAP: FROM DEMENTIA RISK ASSESSMENT TO ADVICE ON RISK REDUCTION	J Prev Alz Dis 2015;2(3):189-198	2384
THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2017;4(4):242-246	2370
THE RELATIONSHIP OF OMEGA 3 POLYUNSATURATED FATTY ACIDS IN RED BLOOD CELL MEMBRANES WITH COGNITIVE FUNCTION AND BRAIN STRUCTURE: A REVIEW FOCUSSED ON ALZHEIMER’S DISEASE	J Prev Alz Dis 2018;5(1):78-84	2336
EVALUATION OF THE NEUROPROTECTIVE POTENTIAL OF N-ACETYLCYSTEINE FOR PREVENTION AND TREATMENT OF COGNITIVE AGING AND DEMENTIA	J Prev Alz Dis 2017;4(3):201-206	2318
CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2016;3(3):138-144	2282
POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAM	J Prev Alz Dis 2015;2(3):165-171	2244
SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL	J Prev Alz Dis 2017;4(1):12-15	2140
SAFETY AND EFFICACY OF LEMBOREXANT IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE DEMENTIA: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIAL	J Prev Alz Dis 2021;1(8):7-18	2140
FROM BRAIN DISEASE TO BRAIN HEALTH: PRIMARY PREVENTION OF ALZHEIMER’S DISEASE AND RELATED DISORDERS IN A HEALTH SYSTEM USING AN ELECTRONIC MEDICAL RECORD-BASED APPROACH	J Prev Alz Dis 2017;4(3):157-164	2138
MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA	J Prev Alz Dis 2014;1(1):13-22	2045
B-VITAMIN THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIAL	J Prev Alz Dis 2017;4(3):174-182	1964
THE CASE FOR USING ACTIGRAPHY GENERATED SLEEP AND ACTIVITY ENDPOINTS IN ALZHEIMER’S DISEASE CLINICAL TRIALS	J Prev Alz Dis 2016;3(3):173-176	1814
INTEGRATED CARE FOR OLDER PEOPLE AND THE IMPLEMENTATION IN THE INSPIRE CARE COHORT	J Prev Alz Dis 2020;7(2):70-74	1811
ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE 2020	J Prev Alz Dis 2020;7(2):66-67	1738
DEPENDENCE LEVELS AS INTERIM CLINICAL MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: 18-MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDY	J Prev Alz Dis 2017;4(2):72-80	1718
THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER’S DISEASE. STRATEGY, METHODS AND INITIAL RESULTS	J Prev Alz Dis 2017;4(3):183-193	1681
ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE	J Prev Alz Dis 2019;6(3):157-163	1681
‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALS	J Prev Alz Dis 2016;3(4):229-235	1635
RATIONALE AND STRUCTURE FOR A NEW CENTER FOR STUDIES ON PREVENTION OF ALZHEIMER’S DISEASE (STOP-AD)	J Prev Alz Dis 2016;3(4):236-242	1618
PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: EFFICACY IN PATIENTS WITH MORE PRONOUNCED PSYCHOTIC SYMPTOMS	J Prev Alz Dis 2019;6(1):27-33	1524
HEALTH LITERACY IN INDIVIDUALS AT RISK FOR ALZHEIMER’S DEMENTIA: A SYSTEMATIC REVIEW	J Prev Alz Dis 2020;7(1):47-55	1508
WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE	J Prev Alz Dis 2018;5(3):171-170	1490
FATTY ACIDS AND ALZHEIMER’S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL	J Prev Alz Dis 2018;5(3):168-170	1445
AN ACTION PLAN TO FACE THE CHALLENGE OF DEMENTIA: INTERNATIONAL STATEMENT ON DEMENTIA FROM IAP FOR HEALTH	J Prev Alz Dis 2018;5(3):207-212	1421
PSYCHOMETRIC PROPERTIES OF THE CLINICAL DEMENTIA RATING – SUM OF BOXES AND OTHER COGNITIVE AND FUNCTIONAL OUTCOMES IN A PRODROMAL ALZHEIMER’S DISEASE POPULATION	J Prev Alz Dis 2021;2(8):151-160	1413
VITAMIN E SUPPLEMENTATION REDUCES CELLULAR LOSS IN THE BRAIN OF A PREMATURE AGING MOUSE MODEL	J Prev Alz Dis 2017;4(4):226-235	1402
NUTRITION-BASED APPROACHES IN CLINICAL TRIALS TARGETING COGNITIVE FUNCTION: HIGHLIGHTS OF THE CTAD 2020	J Prev Alz Dis 2021;2(8):118-122	1400
NANOROBOTS THE FUTURE OF NEUROLOGY: A PERSPECTIVE ON ALZHEIMER’S DISEASE	J Prev Alz Dis 2018;5(2):155-156	1387
IDENTIFYING BETTER OUTCOME MEASURES TO IMPROVE TREATMENT OF AGITATION IN DEMENTIA: A REPORT FROM THE EU/US/CTAD TASK FORCE	J Prev Alz Dis 2018;5(2):98-102	1366
THE FUTURE OF ANTI-AMYLOID TRIALS	J Prev Alz Dis 2020;3(7):146-151	1322
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020	J Prev Alz Dis 2020;7(S1):S2-S54	1296
PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT	J Prev Alz Dis 2019;6(3):169-173	1282
REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCE	J Prev Alz Dis 2016;3(2):68-74	1281
CAN DIGITAL TECHNOLOGY ADVANCE THE DEVELOPMENT OF TREATMENTS FOR ALZHEIMER’S DISEASE?	J Prev Alz Dis 2019;6(4):217-220	1236
PIMAVANSERIN: POTENTIAL TREATMENT FOR DEMENTIA-RELATED PSYCHOSIS	J Prev Alz Dis 2018;5(4):253-258	1200
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CARE	J Prev Alz Dis 2020;3(7):165-170	1178
MULTIDOMAIN INTERVENTIONS TO PREVENT COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, AND DEMENTIA: FROM FINGER TO WORLD-WIDE FINGERS	J Prev Alz Dis 2020;7(1):29-36	1177
NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER’S DISEASE: AN EU/US CTAD TASK FORCE REPORT	J Prev Alz Dis 2020;3(7):152-157	1175
IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUS	J Prev Alz Dis 2019;6(2):78-84	1164
ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASE	J Prev Alz Dis 2019;6(4):232-236	1163
RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES	J Prev Alz Dis 2020;3(7):158-164	1161
TREATABLE VASCULAR RISK AND COGNITIVE PERFORMANCE IN PERSONS AGED 35 YEARS OR OLDER: LONGITUDINAL STUDY OF SIX YEARS	J Prev Alz Dis 2019;6(1):42-49	1130
TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE	J Prev Alz Dis 2020;3(7):184-194	1126
APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY	J Prev Alz Dis 2019;6(4):248-255	1099
THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0	J Prev Alz Dis 2020;7(1):8-13	1090
THE INTERRELATIONSHIP BETWEEN INSULIN-LIKE GROWTH FACTOR 1, APOLIPOPROTEIN E Ε4, LIFESTYLE FACTORS, AND THE AGING BODY AND BRAIN	J Prev Alz Dis 2020;4(7):265-273	1082
A TURNING POINT IN ALZHEIMER’S RESEARCH: HARMONIZED RESEARCH STRATEGIES AND NOVEL INVESTMENTS IN PUBLIC HEALTH INFRASTRUCTURE ARE REENERGIZING THE FIELD, AND REKINDLING HOPE FOR THOSE AFFECTED BY ALZHEIMER’S AND RELATED DEMENTIAS	J Prev Alz Dis 2019;6(4):214-216	1064
CORTICAL Β-AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION	J Prev Alz Dis 2020;7(2):128-134	1063
EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALS	J Prev Alz Dis 2017;4(2):116-124	1060
DIET AS A RISK FACTOR FOR COGNITIVE DECLINE IN AFRICAN AMERICANS AND CAUCASIANS WITH A PARENTAL HISTORY OF ALZHEIMER’S DISEASE: A CROSS- SECTIONAL PILOT STUDY DIETARY PATTERNS	J Prev Alz Dis 2019;6(1):50-55	1052
REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGE	J Prev Alz Dis 2020;7(1):56-64	1047
UTILIZATION OF OBSERVATIONAL DATA AS A PROXY COHORT FOR COMPARISON PURPOSES WITH OPEN-LABEL STUDY RESULTS: AN EXAMPLE FROM ALZHEIMER’S DISEASE	J Prev Alz Dis 2019;6(2):90-99	1008
A MISSED OPPORTUNITY FOR DEMENTIA PREVENTION? CURRENT CHALLENGES FOR EARLY DETECTION AND MODERN-DAY SOLUTIONS	J Prev Alz Dis 2020;4(7):291-293	992
CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIAL	J Prev Alz Dis 2018;5(3):202-206	973
SCREENING FOR MILD COGNITIVE IMPAIRMENT: THERE IS THE WILL BUT IS THERE A WAY?	J Prev Alz Dis 2020;3(7):144-145	958
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING	J Prev Alz Dis 2020;3(7):171-178	951
POSSIBLE ENDPOINTS IN A PRODROMAL ALZHEIMER’S DISEASE TRIAL	J Prev Alz Dis 2015;2(2):88-90	910
POLYGENIC RISK SCORE ANALYSIS OF ALZHEIMER’S DISEASE IN CASES WITHOUT APOE4 OR APOE2 ALLELES	J Prev Alz Dis 2019;6(1):16-19	888
ESTABLISHING CLINICAL RELEVANCE IN PRECLINICAL ALZHEIMER’S DISEASE	J Prev Alz Dis 2015;2(2):85-87	880
IMPACT OF THE COVID-19 OUTBREAK ON THE CLINICAL AND RESEARCH ACTIVITIES OF MEMORY CLINICS: AN ALZHEIMER’S DISEASE CENTER FACING THE COVID-19 CRISIS	J Prev Alz Dis 2020;3(7):197-198	878
DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE: CLINICAL PRACTICE IN 2021	J Prev Alz Dis 2021;3(8):371-386	860
DIGITAL SCREENING FOR COGNITIVE IMPAIRMENT – A PROOF OF CONCEPT STUDY	J Prev Alz Dis 2021;2(8):127-134	856
COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALS	J Prev Alz Dis 2015;2(2):82-84	849
VIEWPOINT: WHEN IT COMES TO LECANEMAB (AND DONANEMAB), HOW MIGHT WE THINK ABOUT ‘REASONABLE AND NECESSARY’?	J Prev Alz Dis 2023;3(10):342-343	848
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS	J Prev Alz Dis 2021;4(8):398-410	844
THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER’S DISEASE DRUG DEVELOPMENT PROGRAMS	J Prev Alz Dis 2020;4(7):288-290	837
HOW WILL ADUCANUMAB APPROVAL IMPACT AD RESEARCH?	J Prev Alz Dis 2021;4(8):391-392	831
PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS	J Prev Alz Dis 2020;4(7):213-218	827
APPLICATION OF DIGITAL COGNITIVE BIOMARKERS FOR ALZHEIMER’S DISEASE: IDENTIFYING COGNITIVE PROCESS CHANGES AND IMPENDING COGNITIVE DECLINE	J Prev Alz Dis 2021;2(8):123-126	809
EVALUATION OF THE FISCAL COSTS AND CONSEQUENCES OF ALZHEIMER’S DISEASE IN GERMANY: MICROSIMULATION OF PATIENTS’ AND CAREGIVERS’ PATHWAYS	J Prev Alz Dis 2022;4(9):758-768	799
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW	J Prev Alz Dis 2020;4(7):208-212	795
THIRTY-SIX-MONTH AMYLOID POSITRON EMISSION TOMOGRAPHY RESULTS SHOW CONTINUED REDUCTION IN AMYLOID BURDEN WITH SUBCUTANEOUS GANTENERUMAB	J Prev Alz Dis 2021;1(8):3-6	792
IMPACT OF ADUHELM APPROVAL ON CARE AND POLICY	J Prev Alz Dis 2021;4(8):396-397	790
TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASE	J Prev Alz Dis 2022;2(9):197-210	787
THE COMPUTERIZED COGNITIVE COMPOSITE (C3) IN A4, AN ALZHEIMER’S DISEASE SECONDARY PREVENTION TRIAL	J Prev Alz Dis 2021;1(8):59-67	774
A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER’S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUP	J Prev Alz Dis 2020;4(7):274-282	762
THE EPIDEMIOLOGY OF ALZHEIMER’S DISEASE MODIFIABLE RISK FACTORS AND PREVENTION	J Prev Alz Dis 2021;3(8):313-321	759
THE ALZHEIMER’S PREVENTION REGISTRY: A LARGE INTERNET-BASED PARTICIPANT RECRUITMENT REGISTRY TO ACCELERATE REFERRALS TO ALZHEIMER’S-FOCUSED STUDIES	J Prev Alz Dis 2020;4(7):242-250	758
NEXT-GENERATION ALZHEIMER’S THERAPEUTICS: LEVERAGING DEEP BIOLOGY	J Prev Alz Dis 2020;3(7):138-139	740
Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021	J Prev Alz Dis 2021;8(S1):S73-S170	736
THE TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD): EXPERIENCE FROM THE FIRST 3 YEARS	J Prev Alz Dis 2020;4(7):234-241	720
AMYLOID AND APOE STATUS OF SCREENED SUBJECTS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM	J Prev Alz Dis 2021;2(8):218-223	720
TOULOUSE ALZHEIMER’S CLINICAL RESEARCH CENTER RECOVERY AFTER THE COVID-19 CRISIS: TELEMEDICINE AN INNOVATIVE SOLUTION FOR CLINICAL RESEARCH DURING THE CORONAVIRUS PANDEMIC	J Prev Alz Dis 2020;4(7):301-304	719
THE US EXPERT PANEL ON THE APPROPRIATE USE RECOMMENDATIONS OF ADUCANUMAB IN CLINICAL PRACTICE	J Prev Alz Dis 2021;4(8):411	718
PUBLIC POLICY SHOULD FOSTER ALZHEIMER’S TREATMENT AVAILABILITY: COMMENT ON THE DRAFT US MEDICARE DECISION TO LIMIT PAYMENT FOR ADUCANUMAB (ADUHELMTM) TO PATIENTS PARTICIPATING IN CLINICAL TRIALS	J Prev Alz Dis 2022;2(9):241-246	690
THE ROLE OF FUTILITY ANALYSES IN AD CLINICAL TRIALS	J Prev Alz Dis 2020;7(1):7	688
LECANEMAB CLARITY AD: QUALITY-OF-LIFE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL IN EARLY ALZHEIMER’S DISEASE	J Prev Alz Dis 2023;4(10):771-777	681
NEW HOPE FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2021;3(8):238-239	678
CONSEQUENCES OF THE FDA DECISION ON ADUCANUMAB FOR PATIENT CARE AND RESEARCH	J Prev Alz Dis 2021;4(8):393-395	673
EDITORIAL: APPROPRIATE USE RECOMMENDATIONS FOR LECANEMAB	J Prev Alz Dis 2023;3(10):356	670
ACCELERATING PRECLINICAL ALZHEIMER’S CLINICAL TRIALS THROUGH A TRIAL-READY COHORT WITH DIVERSE REPRESENTATION	J Prev Alz Dis 2020;4(7):204-205	664
Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021	J Prev Alz Dis 2021;8(S1):S1-S72	664
POLYGENIC RISK SCORING IS AN EFFECTIVE APPROACH TO PREDICT THOSE INDIVIDUALS MOST LIKELY TO DECLINE COGNITIVELY DUE TO ALZHEIMER’S DISEASE	J Prev Alz Dis 2021;1(8):78-83	662
VIEWPOINT: WHAT IS REASONABLE AND NECESSARY FOR PEOPLE LIVING WITH AD AFTER THE FDA APPROVES A TREATMENT?	J Prev Alz Dis 2023;3(10):344-345	655
INTRANASAL INSULIN REDUCES WHITE MATTER HYPERINTENSITY PROGRESSION IN ASSOCIATION WITH IMPROVEMENTS IN COGNITION AND CSF BIOMARKER PROFILES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE	J Prev Alz Dis 2021;3(8):240-248	650
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS	J Prev Alz Dis 2021;4(8):412-413	627
LETTER TO THE EDITOR REFERRING TO AISEN, P.S. AND R. RAMAN, FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020	J Prev Alz Dis 2020;4(7):299-300	623
RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD)	J Prev Alz Dis 2020;4(7):219-225	621
NEUROINFLAMMATION, ITS ROLE IN ALZHEIMER’S DISEASE AND THERAPEUTIC STRATEGIES	J Prev Alz Dis 2023;4(10):686-698	609
AUTHORS RESPONSE TO UMBRICHT D, LETTER TO THE EDITOR REFERRING FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020	J Prev Alz Dis 2020;4(7):300	605
THE CRITICAL ROLE OF BIOMARKERS FOR DRUG DEVELOPMENT TARGETING THE BIOLOGY OF AGING	J Prev Alz Dis 2023;4(10):729-742	590
DOES PLAYING MAHJONG BENEFIT OLDER INDIVIDUALS? A SCOPING REVIEW	J Prev Alz Dis 2024;5(11):1363-1377	581
ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA	J Prev Alz Dis 2021;3(8):257-262	579
TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER’S DISEASE: SENOLYTICS	J Prev Alz Dis 2023;4(10):633-646	578
GEROSCIENCE AND ALZHEIMER’S DISEASE DRUG DEVELOPMENT	J Prev Alz Dis 2023;4(10):620-632	577
THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINE	J Prev Alz Dis 2020;4(7):294-298	569
PROTOCOL FOR THE BRAIN HEALTH SUPPORT PROGRAM STUDY OF THE CANADIAN THERAPEUTIC PLATFORM TRIAL FOR MULTIDOMAIN INTERVENTIONS TO PREVENT DEMENTIA (CANTHUMBS UP): A PROSPECTIVE 12-MONTH INTERVENTION STUDY	J Prev Alz Dis 2023;4(10):875-885	563
TACKLING A MAJOR DEFICIENCY OF DIVERSITY IN ALZHEIMER’S DISEASE THERAPEUTIC TRIALS: AN CTAD TASK FORCE REPORT	J Prev Alz Dis 2022;3(9):388-392	561
GENDER-SPECIFIC DESIGN AND EFFECTIVENESS OF NONPHARMACOLOGICAL INTERVENTIONS AGAINST COGNITIVE DECLINE – SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	J Prev Alz Dis 2023;1(10):69-82	559
MODULATION OF MITOCHONDRIAL FUNCTION AS A THERAPEUTIC STRATEGY FOR NEURODEGENERATIVE DISEASES	J Prev Alz Dis 2023;4(10):675-685	559
ESTABLISHING A TRIAL READY COHORT TO ACCELERATE ALZHEIMER’S CLINICAL TRIAL ENROLLMENT AND TREATMENTS	J Prev Alz Dis 2020;4(7):202-203	556
TRC-PAD: ACCELERATING RECRUITMENT OF AD CLINICAL TRIALS THROUGH INNOVATIVE INFORMATION TECHNOLOGY	J Prev Alz Dis 2020;4(7):226-233	554
EDITORIAL: DIETARY CHOLESTEROL AND DEMENTIA RISK	J Prev Alz Dis 2023;4(10):746-747	543
MESENCHYMAL STEM CELLS MODULATE SIRT1/MIR-134/ GSK3Β SIGNALING PATHWAY IN A RAT MODEL OF ALZHEIMER\'S DISEASE	J Prev Alz Dis 2022;3(9):458-468	541
ALZHEIMER’S DISEASE RESEARCH IN JAPAN: A SHORT HISTORY, CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTION	J Prev Alz Dis 2021;4(8):462-464	528
LONGITUDINAL COURSE OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE IN A COHORT STUDY: METHODS, BASELINE AND LONGITUDINAL RESULTS OF THE A3C STUDY	J Prev Alz Dis 2021;2(8):199-209	511
BEYOND VISION: A VIEW FROM EYE TO ALZHEIMER’S DISEASE AND DEMENTIA	J Prev Alz Dis 2024;2(11):469-483	503
ESTIMATES OF CURRENT CAPACITY FOR DIAGNOSING ALZHEIMER’S DISEASE IN SWEDEN AND THE NEED TO EXPAND SPECIALIST NUMBERS	J Prev Alz Dis 2024;1(11):155-161	501
MAJOR COST DRIVERS IN ASSESSING THE ECONOMIC BURDEN OF ALZHEIMER’S DISEASE: A STRUCTURED, RAPID REVIEW	J Prev Alz Dis 2021;3(8):362-370	498
THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY: A DIGITAL INTERVENTION TO INCREASE RESEARCH PARTICIPATION OF BLACK AMERICAN PARTICIPANTS IN THE BRAIN HEALTH REGISTRY	J Prev Alz Dis 2023;4(10):847-856	496
VALIDATION, DEPLOYMENT, AND REAL-WORLD IMPLEMENTATION OF A MODULAR TOOLBOX FOR ALZHEIMER’S DISEASE DETECTION AND DEMENTIA RISK REDUCTION: THE AD-RIDDLE PROJECT	J Prev Alz Dis 2024;2(11):329-338	489
“TIME SAVED” CALCULATIONS TO IMPROVE DECISION-MAKING IN PROGRESSIVE DISEASE STUDIES	J Prev Alz Dis 2024;3(11):529-536	489
MULTIMODAL PRECISION PREVENTION - A NEW DIRECTION IN ALZHEIMER’S DISEASE	J Prev Alz Dis 2023;4(10):718-728	487
CAN VIRTUAL SCIENTIFIC CONFERENCES FACILITATE TWOWAY LEARNING BETWEEN DEMENTIA RESEARCHERS AND PARTICIPANTS?	J Prev Alz Dis 2021;3(8):387-388	486
LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASE	J Prev Alz Dis 2022;1(9):178-183	472
ANTI-AMYLOID THERAPIES FOR ALZHEIMER’S DISEASE: AN ALZHEIMER EUROPE POSITION PAPER AND CALL TO ACTION	J Prev Alz Dis 2024;2(11):265-273	471
THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE: AMYLOID VS. NON-AMYLOID. WHERE DOES CONSENSUS LIE TODAY? AN CTAD TASK FORCE REPORT	J Prev Alz Dis 2022;2(9):231-235	469
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER\'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT)	J Prev Alz Dis 2021;4(8):425-435	467
THE GERAS SOLUTIONS COGNITIVE TEST FOR ASSESSING COGNITIVE IMPAIRMENT: NORMATIVE DATA FROM A POPULATION-BASED COHORT	J Prev Alz Dis 2023;2(10):207-211	458
IN VIVO DETECTION OF CHANGES RELATED TO CORTICAL COLUMNAR ORGANIZATION AND NEUROINFLAMMATION ACROSS THE AD CONTINUUM	J Prev Alz Dis 2022;4(9):769-779	457
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCH	J Prev Alz Dis 2020;4(7):206-207	455
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS UPDATE	J Prev Alz Dis 2022;2(9):221-230	455
SAFETY, TOLERABILITY, PHARMACOKINETICS AND QUANTITATIVE ELECTROENCEPHALOGRAPHY ASSESSMENT OF ACD856, A NOVEL POSITIVE ALLOSTERIC MODULATOR OF TRK-RECEPTORS FOLLOWING MULTIPLE DOSES IN HEALTHY SUBJECTS	J Prev Alz Dis 2023;4(10):778-789	451
MULTIOMICS BLOOD-BASED BIOMARKERS PREDICT ALZHEIMER’S PREDEMENTIA WITH HIGH SPECIFICITY IN A MULTICENTRIC COHORT STUDY	J Prev Alz Dis 2024;3(11):567-581	450
THE FUTURE OF AD CLINICAL TRIALS WITH THE ADVENT OF ANTI-AMYLOID THERAPIES: AN CTAD TASK FORCE REPORT	J Prev Alz Dis 2022;3(9):393-399	449
DETECTION AND MANAGEMENT OF AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS WITH ALZHEIMER’S DISEASE TREATED WITH ANTI-AMYLOID BETA THERAPY	J Prev Alz Dis 2022;2(9):211-220	447
COST-EFFECTIVENESS OF PREVENTION FOR PEOPLE AT RISK FOR DEMENTIA: A SCOPING REVIEW AND QUALITATIVE SYNTHESIS	J Prev Alz Dis 2024;2(11):402-413	446
DIAGNOSTIC BIOMARKERS OF AMYLOID AND TAU PATHOLOGY IN ALZHEIMER’S DISEASE: AN OVERVIEW OF TESTS FOR CLINICAL PRACTICE IN THE UNITED STATES AND EUROPE	J Prev Alz Dis 2023;3(10):426-442	444
HOW MODIFIABLE ARE MODIFIABLE DEMENTIA RISK FACTORS? A FRAMEWORK FOR CONSIDERING THE MODIFIABILITY OF DEMENTIA RISK FACTORS	J Prev Alz Dis 2024;1(11):22-37	443
PLATFORM TRIALS TO EXPEDITE DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US CTAD TASK FORCE	J Prev Alz Dis 2021;3(8):306-312	436
EDUCATION AS RISK FACTOR OF MILD COGNITIVE IMPAIRMENT: THE LINK TO THE GUT MICROBIOME	J Prev Alz Dis 2024;3(11):759-768	435
DEMENTIA PREVENTION: A GLOBAL CHALLENGE IN URGENT NEED OF SOLUTIONS	J Prev Alz Dis 2022;1(9):1-2	433
A UK-WIDE STUDY EMPLOYING NATURAL LANGUAGE PROCESSING TO DETERMINE WHAT MATTERS TO PEOPLE ABOUT BRAIN HEALTH TO IMPROVE DRUG DEVELOPMENT: THE ELECTRONIC PERSON-SPECIFIC OUTCOME MEASURE (EPSOM) PROGRAMME	J Prev Alz Dis 2021;4(8):448-456	427
HEALTH ECONOMIC CONSIDERATIONS IN THE DEPLOYMENT OF AN ALZHEIMER’S PREVENTION THERAPY	J Prev Alz Dis 2024;2(11):303-309	427
UNSUPERVISED ONLINE PAIRED ASSOCIATES LEARNING TASK FROM THE CAMBRIDGE NEUROPSYCHOLOGICAL TEST AUTOMATED BATTERY (CANTAB®) IN THE BRAIN HEALTH REGISTRY	J Prev Alz Dis 2024;2(11):514-524	426
VORTIOXETINE TREATMENT FOR DEPRESSION IN PATIENTS WITH PRODROMAL VS MILD ALZHEIMER’S DISEASE: A SIXMONTH, OPEN-LABEL, OBSERVATIONAL STUDY	J Prev Alz Dis 2024;2(11):375-381	425
THE INSTITUTE ON METHODS AND PROTOCOLS FOR ADVANCEMENT OF CLINICAL TRIALS IN ADRD (IMPACT-AD): A NOVEL CLINICAL TRIALS TRAINING PROGRAM	J Prev Alz Dis 2021;3(8):286-291	424
TARGETING ENDOGENOUS MECHANISMS OF BRAIN RESILIENCE FOR THE TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2023;4(10):699-705	419
EXPLORING THE ASSOCIATION BETWEEN AMYLOID-Β AND MEMORY MARKERS FOR ALZHEIMER’S DISEASE IN COGNITIVELY UNIMPAIRED OLDER ADULTS	J Prev Alz Dis 2024;2(11):339-347	419
COMPARATIVE ANALYSIS OF DIFFERENT DEFINITIONS OF AMYLOID-Β POSITIVITY TO DETECT EARLY DOWNSTREAM PATHOPHYSIOLOGICAL ALTERATIONS IN PRECLINICAL ALZHEIMER	J Prev Alz Dis 2021;1(8):68-77	417
A PHASE 1 SINGLE-ASCENDING-DOSE TRIAL IN HEALTHY VOLUNTEERS TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF INTRAVENOUS PNT001, A NOVEL MID-DOMAIN TAU ANTIBODY TARGETING CIS-PT231 TAU	J Prev Alz Dis 2024;2(11):366-374	417
MECHANISMS UNDERLYING NON-PHARMACOLOGICAL DEMENTIA PREVENTION STRATEGIES: A TRANSLATIONAL PERSPECTIVE	J Prev Alz Dis 2022;1(9):3-11	416
DONANEMAB (LY3002813) PHASE 1B STUDY IN ALZHEIMER’S DISEASE: RAPID AND SUSTAINED REDUCTION OF BRAIN AMYLOID MEASURED BY FLORBETAPIR F18 IMAGING	J Prev Alz Dis 2021;4(8):414-424	414
VIEWPOINT «COMPOUNDED INTEREST» IN ALZHEIMER’S DISEASE: DO NEW AMYLOID-TARGETING TREATMENTS JUSTIFY THEIR USE	J Prev Alz Dis 2023;3(10):333-335	412
BLOOD DERIVED AMYLOID BIOMARKERS FOR ALZHEIMER’S DISEASE PREVENTION	J Prev Alz Dis 2022;1(9):12-21	411
THE SCOTTISH BRAIN HEALTH SERVICE MODEL: RATIONALE AND SCIENTIFIC BASIS FOR A NATIONAL CARE PATHWAY OF BRAIN HEALTH SERVICES IN SCOTLAND	J Prev Alz Dis 2022;2(9):348-358	409
ORAL HEALTH AS A RISK FACTOR FOR ALZHEIMER DISEASE	J Prev Alz Dis 2024;1(11):249-258	409
LOW AMINO ACID SCORE OF BREAKFAST IS ASSOCIATED WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER JAPANESE ADULTS: A COMMUNITY-BASED LONGITUDINAL STUDY	J Prev Alz Dis 2022;1(9):151-157	408
ESTIMATED INVESTMENT NEED TO INCREASE ENGLAND’S CAPACITY TO DIAGNOSE ELIGIBILITY FOR AN ALZHEIMER’S TREATMENT TO G7 AVERAGE CAPACITY LEVELS	J Prev Alz Dis 2024;4(11):1022-1029	407
DIGITAL THERAPEUTICS FOR MCI AND ALZHEIMER’S DISEASE: A REGULATORY PERSPECTIVE - HIGHLIGHTS FROM THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE (CTAD)	J Prev Alz Dis 2022;2(9):236-240	404
PHASE 2A LEARNINGS INCORPORATED INTO REWIND-LB, A PHASE 2B CLINICAL TRIAL OF NEFLAMAPIMOD IN DEMENTIA WITH LEWY BODIES	J Prev Alz Dis 2024;3(11):549-557	404
MULTIMODAL PREVENTIVE TRIAL FOR ALZHEIMER’S DISEASE: MIND-ADMINI PILOT TRIAL STUDY DESIGN AND PROGRESS	J Prev Alz Dis 2022;1(9):30-39	401
CONSISTENCY BETWEEN TREATMENT EFFECTS ON CLINICAL AND BRAIN ATROPHY OUTCOMES IN ALZHEIMER’S DISEASE TRIALS	J Prev Alz Dis 2024;1(11):38-47	400
MODIFIABLE RISK FACTORS FOR ACCELERATED DECLINE IN PROCESSING SPEED: RESULTS FROM THREE DUTCH POPULATION COHORTS	J Prev Alz Dis 2024;1(11):108-116	396
LECANEMAB: APPROPRIATE USE RECOMMENDATIONS	J Prev Alz Dis 2023;3(10):362-377	394
THE EFFECTS OF DIFFERENT EXERCISE INTERVENTIONS ON PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS	J Prev Alz Dis 2024;3(11):620-631	394
EDITORIAL: CLINICAL IMPLEMENTATION OF LECANEMAB: CHALLENGES, QUESTIONS AND SOLUTIONS	J Prev Alz Dis 2023;3(10):353-355	392
BLOOD BIOMARKERS FROM RESEARCH USE TO CLINICAL PRACTICE: WHAT MUST BE DONE? A REPORT FROM THE EU/US CTAD TASK FORCE	J Prev Alz Dis 2022;4(9):569-579	385
USING DIGITAL TOOLS TO ADVANCE ALZHEIMER’S DRUG TRIALS DURING A PANDEMIC: THE EU/US CTAD TASK FORCE	J Prev Alz Dis 2021;4(8):513-519	381
CAN WE USE BLOOD BIOMARKERS AS ENTRY CRITERIA AND FOR MONITORING DRUG TREATMENT EFFECTS IN CLINICAL TRIALS? A REPORT FROM THE EU/US CTAD TASK FORCE	J Prev Alz Dis 2023;3(10):418-425	379
BASELINE FINDINGS OF PREVENTE4: A DOUBLE-BLIND PLACEBO CONTROLLED CLINICAL TRIAL TESTING HIGH DOSE DHA IN APOE4 CARRIERS BEFORE THE ONSET OF DEMENTIA	J Prev Alz Dis 2023;4(10):810-820	379
UNSUPERVISED PERFORMANCE OF THE COGSTATE BRIEF BATTERY IN THE BRAIN HEALTH REGISTRY: IMPLICATIONS FOR DETECTING COGNITIVE DECLINE	J Prev Alz Dis 2022;2(9):262-268	378
CLINICAL TRIAL ENDPOINTS AND THEIR CLINICAL MEANINGFULNESS IN EARLY STAGES OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2022;3(9):507-522	374
WHAT MATTERS TO PATIENTS WITH ALZHEIMER’S DISEASE AND THEIR CARE PARTNERS? IMPLICATIONS FOR UNDERSTANDING THE VALUE OF FUTURE INTERVENTIONS	J Prev Alz Dis 2022;3(9):550-555	372
SEX MODERATES THE ASSOCIATION BETWEEN FRAILTY AND MILD BEHAVIORAL IMPAIRMENT	J Prev Alz Dis 2022;4(9):692-700	372
24-HOUR BLOOD PRESSURE VARIABILITY VIA AMBULATORY MONITORING AND RISK FOR PROBABLE DEMENTIA IN THE SPRINT TRIAL	J Prev Alz Dis 2024;3(11):684-692	371
THE ROLE OF THYROID DYSFUNCTION IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	J Prev Alz Dis 2023;2(10):276-286	370
GLOBAL ENERGY METABOLISM DEFICIT IN ALZHEIMER DISEASE BRAIN	J Prev Alz Dis 2024;1(11):171-178	368
FIBRIN-TARGETING IMMUNOTHERAPY FOR DEMENTIA	J Prev Alz Dis 2023;4(10):647-660	365
ASSOCIATION OF BLOOD MICRORNA EXPRESSION AND POLYMORPHISMS WITH COGNITIVE AND BIOMARKER CHANGES IN OLDER ADULTS	J Prev Alz Dis 2024;1(11):230-240	365
ELECSYS CEREBROSPINAL FLUID ASSAYS ACCURATELY DISTINGUISH ALZHEIMER’S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION	J Prev Alz Dis 2022;3(9):491-498	362
DECREASED GRAY–WHITE MATTER CONTRAST OF [11C]-PIB UPTAKE IN COGNITIVELY UNIMPAIRED SUBJECTS WITH SEVERE OBSTRUCTIVE SLEEP APNEA	J Prev Alz Dis 2022;3(9):499-506	359
AMYLOID-RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN A COGNITIVELY UNIMPAIRED POPULATION WITH AND WITHOUT CEREBRAL AMYLOID	J Prev Alz Dis 2022;4(9):617-624	359
ADUCANUMAB TRIALS EMERGE BUT DON’T ENGAGE	J Prev Alz Dis 2022;2(9):193-196	356
ORAL TAU AGGREGATION INHIBITOR FOR ALZHEIMER’S DISEASE: DESIGN, PROGRESS AND BASIS FOR SELECTION OF THE 16 MG/DAY DOSE IN A PHASE 3, RANDOMIZED, PLACEBOCONTROLLED TRIAL OF HYDROMETHYLTHIONINE MESYLATE	J Prev Alz Dis 2022;4(9):780-790	356
COGNITIVE PERFORMANCE AND INCIDENT ALZHEIMER’S DEMENTIA IN MEN VERSUS WOMEN	J Prev Alz Dis 2024;1(11):162-170	354
DATA-DRIVEN THRESHOLDING STATISTICALLY BIASES ATN PROFILING ACROSS COHORT DATASETS	J Prev Alz Dis 2024;1(11):185-195	354
A POLYMORPHISM CLUSTER AT THE 2Q12 LOCUS MAY PREDICT RESPONSE TO PIROMELATINE IN PATIENTS WITH MILD ALZHEIMER\'S DISEASE	J Prev Alz Dis 2022;2(9):255-261	353
SEX-DRIVEN DIFFERENCES IN THE EFFECTIVENESS OF INDIVIDUALIZED CLINICAL MANAGEMENT OF ALZHEIMER’S DISEASE RISK	J Prev Alz Dis 2022;4(9):731-742	353
THE EFFECT OF MULTIDOMAIN INTERVENTIONS ON GLOBAL COGNITION, SYMPTOMS OF DEPRESSION AND APATHY – A POOLED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS	J Prev Alz Dis 2022;1(9):96-103	343
DEVELOPMENT OF A MOBILE-FIRST REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIES	J Prev Alz Dis 2023;4(10):857-864	340
PUSHING THROUGH THE BARRIERS: PEER ADVICE TO INCREASE PHYSICAL ACTIVITY AND REDUCE DEMENTIA RISK FROM PARTICIPANTS IN A MASSIVE OPEN ONLINE ALZHEIMER’S FOCUSED COURSE	J Prev Alz Dis 2023;3(10):503-512	339
COMPARATIVE EFFICACY, SAFETY, TOLERABILITY, AND EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF DEMENTIA-RELATED PSYCHOSIS (DRP): A SYSTEMATIC LITERATURE REVIEW	J Prev Alz Dis 2021;4(8):520-533	338
WHERE DO WE GO FROM HERE?	J Prev Alz Dis 2022;2(9):188-189	338
EDITORIAL: THE STATE OF ALZHEIMER’S RESEARCH AND THE PATH FORWARD	J Prev Alz Dis 2023;4(10):617-619	338
BUNTANETAP, A NOVEL TRANSLATIONAL INHIBITOR OF MULTIPLE NEUROTOXIC PROTEINS, PROVES TO BE SAFE AND PROMISING IN BOTH ALZHEIMER’S AND PARKINSON’S PATIENTS	J Prev Alz Dis 2023;1(10):25-33	335
LONGITUDINAL IMPACTS OF PRECISION GREENNESS ON ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;3(11):710-720	335
SITE READINESS FRAMEWORK TO IMPROVE HEALTH SYSTEM PREPAREDNESS FOR A POTENTIAL NEW ALZHEIMER’S DISEASE TREATMENT PARADIGM	J Prev Alz Dis 2022;3(9):542-549	333
NEUROPROTECTIVE EFFECTS OF IVIG AGAINST ALZHEIMER’ S DISEASE VIA REGULATION OF ANTIGEN PROCESSING AND PRESENTATION BY MHC CLASS I MOLECULES IN 3XTG-AD MICE	J Prev Alz Dis 2023;3(10):581-594	333
15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA	J Prev Alz Dis 2022;9(S1):S51-S248	332
EDITORIAL: THE DAWN OF A NEW ERA OF ALZHEIMER’S RESEARCH AND DRUG DEVELOPMENT	J Prev Alz Dis 2022;3(9):385-386	328
EVIDENCE-BASED TOOLS FOR DIETARY ASSESSMENTS IN NUTRITION EPIDEMIOLOGY STUDIES FOR DEMENTIA PREVENTION	J Prev Alz Dis 2022;1(9):49-53	324
THE ‘ADUCANUMAB STORY’: WILL THE LAST CHAPTER SPELL THE END OF THE ‘AMYLOID HYPOTHESIS’ OR MARK A NEW BEGINNING?	J Prev Alz Dis 2022;2(9):190-192	324
TWO-YEAR PROGNOSTIC UTILITY OF PLASMA P217+TAU ACROSS THE ALZHEIMER’S CONTINUUM	J Prev Alz Dis 2023;4(10):828-836	324
“BACK TO BRAAK”: ROLE OF NUCLEUS REUNIENS AND SUBCORTICAL PATHWAYS IN ALZHEIMER’S DISEASE PROGRESSION	J Prev Alz Dis 2024;4(11):1030-1040	324
ARE POPULATION-LEVEL APPROACHES TO DEMENTIA RISK REDUCTION UNDER-RESEARCHED? A RAPID REVIEW OF THE DEMENTIA PREVENTION LITERATURE	J Prev Alz Dis 2024;1(11):241-248	322
THE USE OF EPISODIC MEMORY TESTS FOR SCREENING IN CLINICAL TRIALS FOR EARLY ALZHEIMER’S DISEASE: A COMPARISON OF THE FREE AND CUED SELECTIVE REMINDING TEST (FCSRT) AND THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS)	J Prev Alz Dis 2023;1(10):41-49	315
ASSOCIATIONS OF CARDIOVASCULAR AND NONCARDIOVASCULAR COMORBIDITIES WITH DEMENTIA RISK IN PATIENTS WITH DIABETES: RESULTS FROM A LARGE UK COHORT STUDY	J Prev Alz Dis 2022;1(9):86-91	313
WHO BENEFITED MOST FROM THE INTERNET-BASED CONVERSATIONAL ENGAGEMENT RCT (I-CONECT)? APPLICATION OF THE PERSONALIZED MEDICINE APPROACH TO A BEHAVIORAL INTERVENTION STUDY	J Prev Alz Dis 2024;3(11):639-648	313
ERRATUM TO: EDUCATION AS RISK FACTOR OF MILD COGNITIVE IMPAIRMENT: THE LINK TO THE GUT MICROBIOME	J Prev Alz Dis 2024;3(11):798	310
ASURE CLINICAL TRIAL PROTOCOL: A RANDOMIZED, PLACEBOCONTROLLED, PROOF-OF-CONCEPT STUDY AIMING TO EVALUATE SAFETY AND TARGET ENGAGEMENT FOLLOWING ADMINISTRATION OF TW001 IN EARLY ALZHEIMER’S DISEASE PATIENTS	J Prev Alz Dis 2023;4(10):669-674	309
FEMALE REPRODUCTIVE FACTORS AND RISK OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA: THE HUNT STUDY	J Prev Alz Dis 2024;4(11):1063-1072	307
A CONFORMATIONAL VARIANT OF P53 (U-P53AZ) AS BLOODBASED BIOMARKER FOR THE PREDICTION OF THE ONSET OF SYMPTOMATIC ALZHEIMER’S DISEASE	J Prev Alz Dis 2022;3(9):469-479	305
BURDEN OF ILLNESS IN PEOPLE WITH ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW OF EPIDEMIOLOGY, COMORBIDITIES AND MORTALITY	J Prev Alz Dis 2024;1(11):97-107	302
COGNITIVE TRAINING WITH OLDER ADULTS USING SMARTPHONE AND WEB-BASED APPLICATIONS: A SCOPING REVIEW	J Prev Alz Dis 2024;3(11):693-700	302
PROTOCOL OF A PHASE II RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF S-ADENOSYL METHIONINE IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASE	J Prev Alz Dis 2023;4(10):800-809	301
Editorial: Current Themes and Controversies in the Alzheimer’s Disease Field: Looking Ahead to the ctad Meeting in San Francisco, November 29-December 2 2022	J Prev Alz Dis 2022;9(S1):S3-S4	300
PERFORMANCE OF FULLY-AUTOMATED HIGH-THROUGHPUT PLASMA BIOMARKER ASSAYS FOR ALZHEIMER’S DISEASE IN AMNESTIC MILD COGNITIVE IMPAIRMENT SUBJECTS	J Prev Alz Dis 2024;4(11):1073-1078	299
INVESTIGATING PARTIALLY DISCORDANT RESULTS IN PHASE 3 STUDIES OF ADUCANUMAB	J Prev Alz Dis 2023;2(10):171-177	297
PROJECTED SAVINGS TO CANADIAN PROVINCIAL BUDGETS FROM REDUCED LONG-TERM CARE HOME UTILIZATION DUE TO A DISEASE-MODIFYING ALZHEIMER’S TREATMENT	J Prev Alz Dis 2024;1(11):179-184	297
LETTER TO THE EDITOR: BEYOND FRAILTY IN ALZHEIMER’S DISEASE: SHOULD WE MOVE TO THE CONCEPT OF INTRINSIC CAPACITY?	J Prev Alz Dis 2022;4(9):813-815	294
EDITORIAL: WHAT ARE THE REMAINING CHALLENGES BEFORE BLOODBASED BIOMARKERS FOR ALZHEIMER’S DISEASE CAN BE USED IN CLINICAL PRACTICE?	J Prev Alz Dis 2022;4(9):567-568	294
VALIDITY OF ONLINE VERSUS IN-CLINIC SELF-REPORTED EVERYDAY COGNITION SCALE	J Prev Alz Dis 2022;2(9):269-276	293
COGNITIVE DIGITAL BIOMARKERS FROM AUTOMATED TRANSCRIPTION OF SPOKEN LANGUAGE	J Prev Alz Dis 2022;4(9):791-800	292
15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA	J Prev Alz Dis 2022;9(S1):S8-S50	290
ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW PREVENTION CLINICAL TRIAL	J Prev Alz Dis 2022;4(9):625-634	285
EDITORIAL: THE FUTURE IS NOW: ADVANCING BLOOD-BASED MARKERS	J Prev Alz Dis 2022;4(9):563-564	285
REDUCING THE EFFECTS OF AGEING ON COGNITION WITH THERAPEUTIC INTERVENTION OF AN ORAL MULTI-NUTRIENT: THE REACTION PILOT TRIAL STUDY DESIGN	J Prev Alz Dis 2023;4(10):821-827	284
UNDERSTANDING ONLINE REGISTRY FACILITATORS AND BARRIERS EXPERIENCED BY BLACK BRAIN HEALTH REGISTRY PARTICIPANTS: THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY	J Prev Alz Dis 2023;3(10):551-561	283
LIVING ENVIRONMENT, BUILT ENVIRONMENT AND COGNITIVE FUNCTION AMONG OLDER CHINESE ADULTS: RESULTS FROM A CROSS-SECTIONAL STUDY	J Prev Alz Dis 2022;1(9):126-135	281
EVALUATION OF CLINICAL MEANINGFULNESS OF FORTASYN CONNECT IN TERMS OF “TIME SAVED”	J Prev Alz Dis 2024;4(11):992-997	281
OPPORTUNITIES FOR CELLULAR REJUVENATION IN ALZHEIMER’S DISEASE: HOW EPIGENETIC REPROGRAMMING AND CHAPERONE-MEDIATED AUTOPHAGY ARE ENABLING NEXT GENERATION THERAPEUTIC APPROACHES	J Prev Alz Dis 2023;4(10):661-668	279
THE ROLE OF AΒ IN ALZHEIMER’S DISEASE AS AN EVOLUTIONARY OUTCOME OF OPTIMIZED INNATE IMMUNE DEFENSE	J Prev Alz Dis 2022;4(9):580-588	278
ACU193, A MONOCLONAL ANTIBODY THAT SELECTIVELY BINDS SOLUBLE ASS OLIGOMERS: DEVELOPMENT RATIONALE, PHASE 1 TRIAL DESIGN, AND CLINICAL DEVELOPMENT PLAN	J Prev Alz Dis 2023;1(10):19-24	275
EXAMINING DEMOGRAPHIC FACTORS, PSYCHOSOCIAL WELLBEING AND CARDIOVASCULAR HEALTH IN SUBJECTIVE COGNITIVE DECLINE IN THE BRAIN HEALTH REGISTRY COHORT	J Prev Alz Dis 2024;3(11):787-797	274
VIEWPOINT: AMYLOID-TARGETING NEW THERAPIES FOR ALZHEIMER’S DISEASE: A HEALTH ECONOMICS PERSPECTIVE	J Prev Alz Dis 2023;3(10):349-352	272
ESTABLISHING CLINICALLY MEANINGFUL CHANGE ON OUTCOME ASSESSMENTS FREQUENTLY USED IN TRIALS OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE	J Prev Alz Dis 2023;1(10):9-18	270
WHO BENEFITED THE MOST? EFFECTIVENESS OF A LIFESTYLE INTERVENTION AGAINST COGNITIVE DECLINE IN OLDER WOMEN AND MEN – SECONDARY ANALYSIS OF THE AGEWELL. DE-TRIAL	J Prev Alz Dis 2024;2(11):348-355	269
EDITORIAL: WHAT IS REASONABLE AND NECESSARY FOR ALZHEIMER PATIENTS FROM RANDOMIZED CLINICAL TRIALS TO CLINICAL PRACTICE?	J Prev Alz Dis 2023;3(10):331-332	266
AMYLOID AND TAU PREDICTION OF COGNITIVE AND FUNCTIONAL DECLINE IN UNIMPAIRED OLDER INDIVIDUALS: LONGITUDINAL DATA FROM THE A4 AND LEARN STUDIES	J Prev Alz Dis 2024;4(11):802-813	266
EDITORIAL: BLOOD-BASED BIOMARKERS FOR ALZHEIMER’S DISEASE: ARE WE THERE YET?	J Prev Alz Dis 2022;4(9):565-566	264
OPTIMISING ALZHEIMER’S DISEASE DIAGNOSIS AND TREATMENT: ASSESSING COST-UTILITY OF INTEGRATING BLOOD BIOMARKERS IN CLINICAL PRACTICE FOR DISEASEMODIFYING TREATMENT	J Prev Alz Dis 2024;4(11):928-942	264
THE SHAPE TRAIL TEST IS SENSITIVE IN DIFFERENTIATING OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: A CULTURE-NEUTRAL FIVE-MINUTE TEST	J Prev Alz Dis 2024;4(11):1166-1176	264
ROLES OF TREM2 IN THE PATHOLOGICAL MECHANISM AND THE THERAPEUTIC STRATEGIES OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;6(11):1682-1695	264
EDITORIAL: THE CLINICAL TRIALS ALZHEIMER’S DISEASE (CTAD) MEETING IN SAN FRANCISCO, FALL 2022, WILL BE A VERY EXCITING EVENT!	J Prev Alz Dis 2022;3(9):387	263
NOVEL BLOOD-BASED BIOMARKERS AND DISEASE MODIFYING THERAPIES FOR ALZHEIMER’S DISEASE. ARE WE READY FOR THE NEW ERA?	J Prev Alz Dis 2024;4(11):897-902	263
ASSOCIATION BETWEEN RESTING HEART RATE AND MACHINE LEARNING-BASED BRAIN AGE IN MIDDLE- AND OLDER-AGE	J Prev Alz Dis 2024;4(11):1140-1147	259
EDITORIAL: CHANGE ON CLINICAL TRIAL OUTCOME ASSESSMENTS: THE SEARCH FOR MEANINGFULNESS	J Prev Alz Dis 2023;1(10):5-6	258
VIEWPOINT: BALANCING THE CONFLICTING GOALS FOR TREATMENT OF ALZHEIMER’S DISEASE WITH MONOCLONAL ANTIBODIES	J Prev Alz Dis 2023;3(10):336-338	257
EDITORIAL: USEFULNESS OF ANCHOR BASED METHODS FOR DETERMINING CLINICALLY MEANINGFUL CHANGE IN MCI DUE TO AD	J Prev Alz Dis 2023;1(10):7-8	256
EFFECTIVENESS OF RESISTANCE EXERCISE ON COGNITIVE FUNCTION IN ANIMAL MODELS OF ALZHEIMER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	J Prev Alz Dis 2024;4(11):998-1012	254
ASSOCIATIONS BETWEEN PARTICIPANT CHARACTERISTICS AND PARTICIPANT FEEDBACK ABOUT AN UNSUPERVISED ONLINE COGNITIVE ASSESSMENT IN A RESEARCH REGISTRY	J Prev Alz Dis 2023;3(10):607-614	253
NON-GENETIC RISK FACTORS OF ALZHEIMER’S DISEASE: AN UPDATED UMBRELLA REVIEW	J Prev Alz Dis 2024;4(11):917-927	253
VALIDATION OF THE COGDRISK INSTRUMENT AS PREDICTIVE OF DEMENTIA IN FOUR GENERAL COMMUNITY-DWELLING POPULATIONS	J Prev Alz Dis 2023;3(10):478-487	251
DIGITAL CLOCK DRAWING AS AN ALZHEIMER’S DISEASE SUSCEPTIBILITY BIOMARKER: ASSOCIATIONS WITH GENETIC RISK SCORE AND APOE IN OLDER ADULTS	J Prev Alz Dis 2024;1(11):79-87	250
ASSOCIATION OF COGNITIVE RESERVE INDICATOR WITH COGNITIVE DECLINE AND STRUCTURAL BRAIN DIFFERENCES IN MIDDLE AND OLDER AGE: FINDINGS FROM THE UK BIOBANK	J Prev Alz Dis 2024;3(11):739-748	250
COMMENTARY: CLINICAL EFFICACY IN INDIVIDUAL PATIENTS TREATED WITH LECANEMAB	J Prev Alz Dis 2023;3(10):378-379	249
PREFERENCES ABOUT FUTURE ALZHEIMER’S DISEASE TREATMENTS ELICITED THROUGH AN ONLINE SURVEY USING THE THRESHOLD TECHNIQUE	J Prev Alz Dis 2023;4(10):756-764	246
EDITORIAL: ACCELERATING INNOVATIONS FOR ENHANCED BRAIN HEALTH. CAN ARTIFICIAL INTELLIGENCE ADVANCE NEW PATHWAYS FOR DRUG DISCOVERY FOR ALZHEIMER’S AND OTHER NEURODEGENERATIVE DISORDERS?	J Prev Alz Dis 2023;1(10):1-4	244
ASSOCIATION BETWEEN NEUROPSYCHOLOGICAL PERFORMANCE AND CSF PROFILE IN SUBJECTIVE COGNITIVE DECLINE: TOWARDS THE DIAGNOSIS OF PRECLINICAL AD	J Prev Alz Dis 2023;3(10):523-529	243
CHARACTERIZING CLINICAL PROGRESSION IN COGNITIVELY UNIMPAIRED OLDER INDIVIDUALS WITH BRAIN AMYLOID: RESULTS FROM THE A4 STUDY	J Prev Alz Dis 2024;4(11):814-822	243
EDITORIAL: EXPANDING THE ATN FRAMEWORK TO FURTHER PERSONALIZE THERAPIES	J Prev Alz Dis 2023;3(10):380	241
SYSTEMATIC AND COMPARATIVE ANALYSIS OF THE BURDEN OF ALZHEIMER´S DISEASE AND OTHER DEMENTIAS IN MEXICO. RESULTS AT THE NATIONAL AND SUBNATIONAL LEVELS, 1990- 2019	J Prev Alz Dis 2023;1(10):120-129	238
UNDERSTANDING BARRIERS AND FACILITATORS TO SIGNING UP FOR A MOBILE-RESPONSIVE REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIES	J Prev Alz Dis 2023;4(10):865-874	238
CLINICAL MEANINGFULNESS IN ALZHEIMER’S DISEASE CLINICAL TRIALS. A REPORT FROM THE EU-US CTAD TASK FORCE	J Prev Alz Dis 2024;5(11):1219-1227	237
LETTER TO THE EDITOR: AMBAR: A THERAPEUTICAL APPROACH FOR ALZHEIMER’S DISEASE PATIENTS REGARDLESS OF AMYLOID STATUS	J Prev Alz Dis 2023;1(10):148-149	236
COMPUTERIZED COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENT: FINDINGS IN AFRICAN AMERICANS AND CAUCASIANS	J Prev Alz Dis 2024;1(11):149-154	235
ECONOMIC IMPACT OF PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER DISEASE IN THE UNITED STATES	J Prev Alz Dis 2024;4(11):983-991	235
BIOMARKERS AND COGNITION STUDY, SINGAPORE (BIOCIS): PROTOCOL, STUDY DESIGN, AND PRELIMINARY FINDINGS	J Prev Alz Dis 2024;4(11):1093-1105	235
PERIODONTAL DISEASE AND ALZHEIMER’S: INSIGHTS FROM A SYSTEMATIC LITERATURE NETWORK ANALYSIS	J Prev Alz Dis 2024;4(11):1148-1165	234
LONGITUDINAL PHOSPHO-TAU217 PREDICTS AMYLOID POSITRON EMISSION TOMOGRAPHY IN ASYMPTOMATIC ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;4(11):823-830	234
EDITORIAL: LECANEMAB: APPROPRIATE USE RECOMMENDATIONS – A COMMENTARY FROM A EUROPEAN PERSPECTIVE	J Prev Alz Dis 2023;3(10):357-358	232
ANTIHYPERTENSIVE AGENTS AND INCIDENT ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES	J Prev Alz Dis 2022;4(9):715-724	231
PREDICTING PROGRESSION FROM NORMAL TO MCI AND FROM MCI TO AD USING CLINICAL VARIABLES IN THE NATIONAL ALZHEIMER’S COORDINATING CENTER UNIFORM DATA SET VERSION 3: APPLICATION OF MACHINE LEARNING MODELS AND A PROBABILITY CALCULATOR	J Prev Alz Dis 2023;2(10):301-313	230
UTILITY OF ENVIRONMENTAL COMPLEXITY AS A PREDICTOR OF ALZHEIMER’S DISEASE DIAGNOSIS: A BIG-DATA MACHINE LEARNING APPROACH	J Prev Alz Dis 2023;2(10):223-235	229
EDITORIAL: IMPLICATIONS OF EMERGING USES OF GENETIC TESTING FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2023;3(10):359-361	229
‘TIME SAVED’ AS A DEMONSTRATION OF CLINICAL MEANINGFULNESS AND ILLUSTRATED USING THE DONANEMAB TRAILBLAZER-ALZ STUDY FINDINGS	J Prev Alz Dis 2023;3(10):595-599	229
EDITORIAL: INTRODUCTION TO THE SPECIAL ISSUE ON THE A4 STUDY	J Prev Alz Dis 2024;4(11):801	228
LONGITUDINAL TRAJECTORIES OF THE COGNITIVE FUNCTION INDEX IN THE A4 STUDY	J Prev Alz Dis 2024;4(11):838-845	228
COHORT EFFECTS IN ALZHEIMER’S DISEASE TRIALS: AN EMPIRICAL ASSESSMENT UTILIZING DATA FROM THE ALZHEIMER’S DISEASE COOPERATIVE STUDY	J Prev Alz Dis 2023;3(10):471-477	226
CROSS-SECTIONAL AND LONGITUDINAL COMPARISON OF TAU IMAGING WITH 18F-MK6240 AND 18F-FLORTAUCIPIR IN POPULATIONS MATCHED FOR AGE, MMSE AND BRAIN BETA-AMYLOID BURDEN	J Prev Alz Dis 2023;2(10):251-258	222
VIEWPOINT: CLINICIANS’ PERSPECTIVES ON HOW DISEASE MODIFYING DRUGS FOR ALZHEIMER’S DISEASE IMPACT SPECIALTY CARE	J Prev Alz Dis 2023;3(10):339-341	219
CHANGE IN DIGITAL COGNITIVE TEST PERFORMANCE BETWEEN SOLANEZUMAB AND PLACEBO GROUPS IN PRECLINICAL ALZHEIMER’S DISEASE: SECONDARY ANALYSES FROM THE A4 STUDY	J Prev Alz Dis 2024;4(11):846-856	219
OUTREACH, SCREENING, AND RANDOMIZATION OF APOE Ε4 CARRIERS INTO AN ALZHEIMER’S PREVENTION TRIAL: A GLOBAL PERSPECTIVE FROM THE API GENERATION PROGRAM	J Prev Alz Dis 2023;3(10):453-463	215
RELATIONSHIP BETWEEN PLASMA P-TAU217 AND AMYLOID PET IN RACIAL AND ETHNIC UNDERREPRESENTED GROUPS (REURG) COMPARED WITH NON RE-URG IN LEARN AND A4	J Prev Alz Dis 2024;4(11):831-837	215
Editorial: We Have Turned the Corner	J Prev Alz Dis 2022;9(S1):S5-S6	214
ERRATUM TO: DIGITAL CLOCK DRAWING AS AN ALZHEIMER’S DISEASE SUSCEPTIBILITY BIOMARKER: ASSOCIATIONS WITH GENETIC RISK SCORE AND APOE IN OLDER ADULTS	J Prev Alz Dis 2024;1(11):263	209
COMBINED EVIDENCE FOR A LONG-TERM, CLINICAL SLOWING EFFECT OF MULTINUTRIENT INTERVENTION IN PRODROMAL ALZHEIMER’S DISEASE: POST-HOC ANALYSIS OF 3-YEAR DATA FROM THE LIPIDIDIET TRIAL	J Prev Alz Dis 2023;3(10):464-470	204
GREATER WHITE MATTER HYPERINTENSITY VOLUME IS ASSOCIATED WITH THE NUMBER OF MICROHEMORRHAGES IN PRECLINICAL ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;4(11):869-873	195
CLINICAL DEVELOPMENT OF ADUCANUMAB, AN ANTI-A? HUMAN MONOCLONAL ANTIBODY BEING INVESTIGATED FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE	J Prev Alz Dis 2017;4(4):255-263	193
MAXIMIZING THE UTILITY OF ALZHEIMER’S DISEASE TRIAL DATA: SHARING OF BASELINE A4 AND LEARN DATA	J Prev Alz Dis 2024;4(11):889-894	193
SAFETY PROFILE OF A COGNITIVELY UNIMPAIRED OLDER POPULATION WITH ELEVATED CEREBRAL AMYLOID IN A 4.5- YEAR CLINICAL TRIAL	J Prev Alz Dis 2024;4(11):857-868	192
VIEWPOINT: DEFINING FDA APPROVED TREATMENTS AS REASONABLE AND NECESSARY: PERSPECTIVES OF INDIVIDUALS LIVING WITH ALZHEIMER’S DISEASE AND CARE PARTNERS	J Prev Alz Dis 2023;3(10):346-348	190
DETECTION RATES OF MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE FOR THE UNITED STATES MEDICARE POPULATION	J Prev Alz Dis 2024;1(11):7-12	188
PRE-RANDOMIZATION PREDICTORS OF STUDY DISCONTINUATION IN A PRECLINICAL ALZHEIMER’S DISEASE RANDOMIZED CONTROLLED TRIAL	J Prev Alz Dis 2024;4(11):874-880	185
EXAMINING THE ROLE OF COMMUNITY ENGAGEMENT IN ENHANCING THE PARTICIPATION OF RACIAL AND ETHNIC MINORITIZED COMMUNITIES IN ALZHEIMER’S DISEASE CLINICAL TRIALS; A RAPID REVIEW	J Prev Alz Dis 2024;6(11):1647-1672	185
PROGRESS IN THE TREATMENT OF ALZHEIMER’S DISEASE IS NEEDED – POSITION STATEMENT OF EUROPEAN ALZHEIMER’S DISEASE CONSORTIUM (EADC) INVESTIGATORS	J Prev Alz Dis 2024;5(11):1212-1218	184
VALIDATION OF A COMMUNITY-BASED APPROACH TOWARD PERSONALIZED DEMENTIA RISK REDUCTION: THE KIMEL FAMILY CENTRE FOR BRAIN HEALTH AND WELLNESS	J Prev Alz Dis 2024;5(11):1455-1466	178
EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?	J Prev Alz Dis 2019;6(3):150	177
PREVALENCE ESTIMATION OF DEMENTIA/ALZHEIMER’S DISEASE USING HEALTH AND RETIREMENT STUDY DATABASE IN THE UNITED STATES	J Prev Alz Dis 2024;5(11):1183-1188	177
PLASMA BIOMARKERS OF ALZHEIMER’S DISEASE AND NEURODEGENERATION ACCORDING TO SOCIODEMOGRAPHIC CHARACTERISTICS AND CHRONIC HEALTH CONDITIONS	J Prev Alz Dis 2024;5(11):1189-1197	174
LETTER TO THE EDITOR: UPDATE TO: TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;4(11):1178-1179	172
PERFORMANCE OF PLASMA BIOMARKERS COMBINED WITH STRUCTURAL MRI TO IDENTIFY CANDIDATE PARTICIPANTS FOR ALZHEIMER’S DISEASE-MODIFYING THERAPY	J Prev Alz Dis 2024;5(11):1198-1205	169
ESTIMATING SOCIO-ECONOMIC STATUS FOR ALZHEIMER’S DISEASE TRIALS	J Prev Alz Dis 2024;5(11):1418-1425	166
INITIAL EXPERIENCE WITH LECANEMAB AND LESSONS LEARNED IN 71 PATIENTS IN A REGIONAL MEDICAL CENTER	J Prev Alz Dis 2024;6(11):1549-1562	156
LOWER INCIDENCE OF DEMENTIA FOLLOWING CANCER DIAGNOSES: EVIDENCE FROM A LARGE COHORT AND MENDELIAN RANDOMIZATION STUDY	J Prev Alz Dis 2024;5(11):1397-1405	155
MULTIDOMAIN INTERVENTION TRIAL FOR PREVENTING COGNITIVE DECLINE AMONG OLDER ADULTS WITH TYPE 2 DIABETES: J-MIND-DIABETES	J Prev Alz Dis 2024;6(11):1604-1614	155
MEDICAL COSTS AND CAREGIVER BURDEN OF DELIVERING DISEASE-MODIFYING ALZHEIMER’S TREATMENTS WITH DIFFERENT DURATION AND ROUTE OF ADMINISTRATION	J Prev Alz Dis 2024;5(11):1384-1389	154
JAPANESE SUBGROUP ANALYSES FROM EMERGE AND ENGAGE, PHASE 3 CLINICAL TRIALS OF ADUCANUMAB IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;5(11):1260-1269	154
DEVELOPMENT AND VALIDATION THE MOBILE TOOLBOX (MTB) SPELLING TEST	J Prev Alz Dis 2024;6(11):1673-1681	150
THE ALZMATCH PILOT STUDY - FEASIBILITY OF REMOTE BLOOD COLLECTION OF PLASMA BIOMARKERS FOR PRECLINICAL ALZHEIMER’S DISEASE TRIALS	J Prev Alz Dis 2024;5(11):1435-1444	148
EDITORIAL: ON THE 2024 ALZHEIMER’S ASSOCIATION CRITERIA: STILL NOT READY FOR CLINICAL USE	J Prev Alz Dis 2024;4(11):895-896	147
BLOOD CATHEPSINS ON THE RISK OF ALZHEIMER’S DISEASE AND RELATED PATHOLOGICAL BIOMARKERS: RESULTS FROM OBSERVATIONAL COHORT AND MENDELIAN RANDOMIZATION STUDY	J Prev Alz Dis 2024;6(11):1834-1842	145
FLAVONOID-RICH FRUIT INTAKE IN MIDLIFE AND LATE-LIFE AND ASSOCIATIONS WITH RISK OF DEMENTIA: THE FRAMINGHAM HEART STUDY	J Prev Alz Dis 2024;5(11):1270-1279	144
DIAGNOSTIC ACCURACY OF PLASMA P-TAU217 FOR DETECTING PATHOLOGICAL CEREBROSPINAL FLUID CHANGES IN COGNITIVELY UNIMPAIRED SUBJECTS USING THE LUMIPULSE PLATFORM	J Prev Alz Dis 2024;6(11):1581-1591	144
A PILOT STUDY OF BRAIN BOOTCAMP, A LOW-INTENSITY INTERVENTION ON DIET, EXERCISE, COGNITIVE ACTIVITY, AND SOCIAL INTERACTION TO IMPROVE OLDER ADULTS’ DEMENTIA RISK SCORES	J Prev Alz Dis 2024;5(11):1500-1512	143
METABOLIC SYNDROME STATUS CHANGES AND COGNITIVE FUNCTIONING: INSIGHTS FROM THE LIFELINES COHORT STUDY	J Prev Alz Dis 2024;5(11):1283-1290	140
DIGITAL HEALTH TECHNOLOGIES FOR ALZHEIMER’S DISEASE AND RELATED DEMENTIAS: INITIAL RESULTS FROM A LANDSCAPE ANALYSIS AND COMMUNITY COLLABORATIVE EFFORT	J Prev Alz Dis 2024;5(11):1480-1489	140
HEIGHTENED PREVALENCE OF COMMON HOSPITAL-TREATED INFECTIONS PRECEDING DEMENTIA DIAGNOSIS WITH ACCELERATED DEMENTIA ONSET AFTER INFLUENZA	J Prev Alz Dis 2024;5(11):1445-1454	139
RISK OF DEMENTIA IN KOREAN VIETNAM WAR VETERANS	J Prev Alz Dis 2024;5(11):1378-1383	134
A STATISTICAL FRAMEWORK FOR ASSESSING THE RELATIONSHIP BETWEEN BIOMARKERS AND CLINICAL ENDPOINTS IN ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;5(11):1228-1240	131
PERFORMANCE OF A SHORT VERSION OF THE EVERYDAY COGNITION SCALE (ECOG-12) TO DETECT COGNITIVE IMPAIRMENT	J Prev Alz Dis 2024;6(11):1741-1750	130
DEVELOPMENT AND CONCURRENT VALIDITY OF THE SHORTFORM COGDRISK DEMENTIA RISK ASSESSMENT TOOL	J Prev Alz Dis 2024;6(11):1751-1758	129
POTENTIALLY MODIFIABLE DEMENTIA RISK FACTORS IN CANADA: AN ANALYSIS OF CANADIAN LONGITUDINAL STUDY ON AGING WITH A MULTI-COUNTRY COMPARISON	J Prev Alz Dis 2024;5(11):1490-1499	128
UNIVERSAL PREVENTION OF DEMENTIA IN ITALY: A DOCUMENT ANALYSIS OF THE 21 ITALIAN REGIONAL PREVENTION PLANS	J Prev Alz Dis 2024;6(11):1525-1533	128
CORRELATES OF SUBJECTIVE COGNITIVE DECLINE IN BLACK AMERICAN MEN	J Prev Alz Dis 2024;6(11):1734-1740	125
DEVELOPING DISEASE-MODIFYING TREATMENTS IN ALZHEIMER’S DISEASE – A PERSPECTIVE FROM ROCHE AND GENENTECH	J Prev Alz Dis 2017;4(4):264-272	124
CONTINUOUS ASSOCIATIONS BETWEEN REMOTE SELFADMINISTERED COGNITIVE MEASURES AND IMAGING BIOMARKERS OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;5(11):1467-1479	122
NO ASSOCIATION FOUND: ADVERSE CHILDHOOD EXPERIENCES AND COGNITIVE IMPAIRMENT IN OLDER AUSTRALIAN ADULTS	J Prev Alz Dis 2024;6(11):1818-1825	112
QUANTIFYING PERSONALIZED SHIFT-WORK MOLECULAR PORTRAITS UNDERLYING ALZHEIMER’S DISEASE THROUGH COMPUTATIONAL BIOLOGY	J Prev Alz Dis 2024;6(11):1721-1733	108
EFFECTS OF THE COVID-19 PANDEMIC ON THE NUMBER OF NEW DEMENTIA DIAGNOSES AND THE QUALITY OF DEMENTIA DIAGNOSTICS AND TREATMENT	J Prev Alz Dis 2024;6(11):1703-1711	108
PHASE 1 STUDIES OF THE ANTI-TAU MONOCLONAL ANTIBODY JNJ-63733657 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;6(11):1592-1603	108
LEVERAGING DIVERSE REGULATED CELL DEATH PATTERNS TO IDENTIFY DIAGNOSIS BIOMARKERS FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;6(11):1775-1788	103
ANTI-HYPERTENSIVES REDUCE THE RATE OF ALZHEIMER’S DISEASE PROGRESSION: A COHORT STUDY LINKED WITH GENETIC AND NEUROPATHOLOGICAL ANALYSES	J Prev Alz Dis 2024;6(11):1634-1646	102
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS	J Prev Alz Dis 2017;4(4):282-428	100
EDITORIAL: AMPLIFYING EFFICIENCY AND ACCURACY IN DEMENTIA DRUG DEVELOPMENT	J Prev Alz Dis 2024;5(11):1180-1182	97
ACOUSTIC SPEECH ANALYSIS IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	J Prev Alz Dis 2024;6(11):1789-1797	95
INFORMING ALZHEIMER’S BIOMARKER COMMUNICATION: CONCERNS AND UNDERSTANDING OF COGNITIVELY UNIMPAIRED ADULTS DURING AMYLOID RESULTS DISCLOSURE	J Prev Alz Dis 2024;6(11):1572-1580	92
A PILOT ELECTROENCEPHALOGRAPHY STUDY OF THE EFFECT OF CT1812 TREATMENT ON SYNAPTIC ACTIVITY IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;6(11):1809-1817	89
ASSOCIATION BETWEEN COGNITIVE RESERVE INDICATOR AND CHRONIC DISEASE-FREE SURVIVAL: A LARGE COMMUNITYBASED LONGITUDINAL STUDY	J Prev Alz Dis 2024;6(11):1712-1720	88
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS	J Prev Alz Dis 2018;5(S1):S1-S196	86
COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE	J Prev Alz Dis 2019;6(3):164-168	86
DEVELOPMENT REVIEW OF THE BACE1 INHIBITOR LANABECESTAT (AZD3293/LY3314814)	J Prev Alz Dis 2017;4(4):247-254	85
DAYTIME SLEEPINESS, APNEA, NEUROIMAGING CORRELATES AND CORTISOL DYSREGULATION IN A MEMORY CLINIC COHORT	J Prev Alz Dis 2024;6(11):1798-1808	85
FREE RECALL OUTPERFORMS STORY RECALL IN ASSOCIATIONS WITH PLASMA BIOMARKERS IN PRECLINICAL ALZHEIMER DISEASE	J Prev Alz Dis 2024;6(11):1696-1702	85
MODULATORY EFFECT OF BLOOD LDL CHOLESTEROL ON THE ASSOCIATION BETWEEN CEREBRAL AΒ AND TAU DEPOSITION IN OLDER ADULTS	J Prev Alz Dis 2024;6(11):1767-1774	84
EDITORIAL: TAU BASED THERAPEUTICS: ALTERNATIVE APPROACHES IN THE WAR ON ALZHEIMER’S DISEASE	J Prev Alz Dis 2019;6(3):151-152	82
WHAT WE LEARN FROM THE CTAD 2018 (CLINICAL TRIALS ALZHEIMER’S DISEASE)	J Prev Alz Dis 2018;5(4):214-215	81
THE 2018 REVISED FDA GUIDANCE FOR EARLY ALZHEIMER’S DISEASE: ESTABLISHING THE MEANINGFULNESS OF TREATMENT EFFECTS	J Prev Alz Dis 2019;6(4):223-227	81
HYPOTHETICAL INTERVENTIONS ON CARDIOVASCULAR HEALTH METRICS FOR ABNORMAL COGNITIVE AGING: AN APPLICATION OF THE PARAMETRIC G-FORMULA IN THE CLHLS COHORT STUDY WITH 12 YEARS FOLLOW-UP	J Prev Alz Dis 2024;6(11):1615-1625	80
TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER’S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDY	J Prev Alz Dis 2019;6(3):192-197	78
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS	J Prev Alz Dis 2014;1(3):214-296	75
EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE?	J Prev Alz Dis 2019;6(3):153-154	75
VIEWS AND PERCEPTIONS OF AMYLOID IMAGING IN A PRECLINICAL ALZHEIMER’S DISEASE TRIAL	J Prev Alz Dis 2024;6(11):1563-1571	74
EDITORIAL: BLOOD TESTS FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS	J Prev Alz Dis 2019;6(3):155-156	70
DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER’S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER’S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB)	J Prev Alz Dis 2018;5(1):15-20	67
EFFECTIVENESS OF A META-COGNITIVE GROUP INTERVENTION FOR OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE OR MILD COGNITIVE IMPAIRMENT: THE ASPIRE RANDOMIZED CONTROLLED TRIAL	J Prev Alz Dis 2024;6(11):1534-1548	66
BIOMARKER AND CLINICAL TRIAL DESIGN SUPPORT FOR DISEASE-MODIFYING THERAPIES: REPORT OF A SURVEY OF THE EU/US: ALZHEIMER’S DISEASE TASK FORCE	J Prev Alz Dis 2018;5(2):103-109	64
PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE	J Prev Alz Dis 2015;2(3):184-188	58
TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALS	J Prev Alz Dis 2018;5(1):31-35	58
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE	J Prev Alz Dis 2019;6(3):180-181	54
EDITORIAL: ICOPE HEALTHY LONGEVITY INTEGRATIVE PREVENTIVE CARE, ALZHEIMER’S DISEASE PREVENTION AND EARLY DIAGNOSIS	J Prev Alz Dis 2024;6(11):1523-1524	54
RESULTS FROM A PHASE II STUDY TO ASSESS THE CLINICAL AND IMMUNOLOGICAL ACTIVITY OF AFFITOPE® AD02 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE	J Prev Alz Dis 2015;2(2):103-114	52
A KETO-MEDIET APPROACH WITH COCONUT SUBSTITUTION AND EXERCISE MAY DELAY THE ONSET OF ALZHEIMER’S DISEASE AMONG MIDDLE-AGED	J Prev Alz Dis 2017;4(1):51-57	52
A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF THE EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY, SAFETY AND AMYLOID IMAGING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE	J Prev Alz Dis 2016;3(4):192-201	52
DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE	J Prev Alz Dis 2018;5(1):8-14	52
THE ROAD AHEAD TO CURE ALZHEIMER\'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS	J Prev Alz Dis 2014;1(3):181-202	50
ADVANCING ALZHEIMER’S DISEASE TREATMENT: LESSONS FROM CTAD 2018	J Prev Alz Dis 2019;6(3):198-203	49
CONTINUING PROGRESS IN ALZHEIMER’S DISEASE TRIALS: CAUSE FOR OPTIMISM	J Prev Alz Dis 2017;4(4):211-212	48
COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER’S DISEASE LIQUID BIOPSY	J Prev Alz Dis 2019;6(3):182-184	48
OVERSIMPLIFICATION OF DEMENTIA RISK REDUCTION MESSAGING IS A THREAT TO KNOWLEDGE TRANSLATION IN DEMENTIA PREVENTION RESEARCH	J Prev Alz Dis 2018;5(1):2-4	47
PLASMA BIOMARKER FOR ALZHEIMER’S DISEASE: ARE WE READY NOW FOR CLINICAL PRACTICE AND DRUG TRIALS?	J Prev Alz Dis 2018;5(3):158-159	47
MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL POPULATION	J Prev Alz Dis 2019;6(3):185-191	47
ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: THE ROAD AHEAD	J Prev Alz Dis 2015;2(2):78-79	46
IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED	J Prev Alz Dis 2014;1(1):40-45	45
ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDY	J Prev Alz Dis 2019;6(2):85-89	45
E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS	J Prev Alz Dis 2014;1(2):110-116	43
LONGITUDINAL TRAJECTORIES OF CLINICAL DECLINE IN AMYLOID POSITIVE AND NEGATIVE POPULATIONS	J Prev Alz Dis 2016;3(2):92-100	43
GLOBAL ALZHEIMER’S PLATFORM TRIAL READY COHORTS FOR THE PREVENTION OF ALZHEIMER’S DEMENTIA	J Prev Alz Dis 2016;3(4):185-187	43
COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ?	J Prev Alz Dis 2019;6(3):174-176	43
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEP	J Prev Alz Dis 2019;6(3):179	43
DRUG DEVELOPMENT IN AD: POINT OF VIEW FROM THE INDUSTRY	J Prev Alz Dis 2015;2(4):216-218	41
UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASE	J Prev Alz Dis 2014;1(3):168-175	40
VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY	J Prev Alz Dis 2016;3(2):75-84	40
ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER’S DISEASE TRIALS	J Prev Alz Dis 2015;2(1):2-3	39
RECRUITMENT OF AT-RISK PARTICIPANTS FOR CLINICAL TRIALS: A MAJOR PARADIGM SHIFT FOR ALZHEIMER’S DISEASE PREVENTION	J Prev Alz Dis 2017;4(4):213-214	39
THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) FINDINGS FROM THE EXPEDITION3 TRIAL	J Prev Alz Dis 2018;5(2):134-136	39
THE ROAD AHEAD TO CURE AND PREVENT ALZHEIMER’S DISEASE: IMPLEMENTING PREVENTION INTO PRIMARY CARE	J Prev Alz Dis 2015;2(3):199-211	38
PREVENTION: HOW THE PARADIGM IS SHIFTING	J Prev Alz Dis 2014;1(1):51-55	37
COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALS	J Prev Alz Dis 2019;6(3):177-178	37
EDITORIAL: JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE (JPAD): BUILDING A “FLEET” AGAINST ALZHEIMER’S DISEASE	J Prev Alz Dis 2014;1(1):2-3	36
PRIMARY PREVENTION OF DEMENTIA: THE FUTURE OF POPULATION-BASED MULTIDOMAIN LIFESTYLE INTERVENTIONS	J Prev Alz Dis 2018;5(1):5-7	36
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2016;3(4):243-259	35
FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLS	J Prev Alz Dis 2017;4(2):100-108	35
NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGES	J Prev Alz Dis 2015;2(3):155-156	34
HEALTHYBRAINS.ORG: FROM REGISTRY TO RANDOMIZATION	J Prev Alz Dis 2016;3(3):123-126	34
GETTING MORE CLINICALLY MEANINGFUL MEASURES OF FUNCTIONAL IMPAIRMENT FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2017;4(2):67-68	34
EDITORIAL : DEMENTIA PREVENTION STRATEGIES – BEYOND THE RANDOMIZED CONTROLLED TRIAL?	J Prev Alz Dis 2014;1(2):62-64	33
INTERVENTIONS TO PREVENT COGNITIVE DECLINE AND DEMENTIA IN ADULTS WITHOUT COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW	J Prev Alz Dis 2015;2(1):38-45	33
METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALES	J Prev Alz Dis 2015;2(2):91-102	33
BEYOND THE CONTROVERSY ON Aß BLOOD-BASED BIOMARKERS	J Prev Alz Dis 2015;2(1):51-55	32
TRIAL DESIGN FOR THE EVALUATION OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: CONSIDERATIONS AND RECOMMENDATIONS	J Prev Alz Dis 2015;2(3):163-164	32
AT A CROSSROADS: A PERSPECTIVE ON DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE IN 2016	J Prev Alz Dis 2016;3(4):181-184	31
PROSPECTIVE EVALUATION OF COGNITIVE HEALTH AND RELATED FACTORS IN ELDERLY AT RISK FOR DEVELOPING ALZHEIMER’S DEMENTIA: A LONGITUDINAL COHORT STUDY	J Prev Alz Dis 2019;6(4):256-266	31
EDITORIAL : THE BRAINHEALTHREGISTRY.ORG: USING THE INTERNET FOR IDENTIFICATION, ASSESSMENT, SCREENING, RECRUITMENT, AND LONGITUDINAL MONITORING OF SUBJECTS FOR NEUROSCIENCE AND ALZHEIMER’S DISEASE STU	J Prev Alz Dis 2014;1(2):59-61	30
PRIMARY PREVENTION OF DEMENTIA: AN EPIDEMIOLOGICAL POINT OF VIEW	J Prev Alz Dis 2016;3(3):160-163	30
CTAD 2016 abstract: EXPEDITION3: A PHASE 3 TRIAL OF SOLANEZUMAB IN MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE		30
EFFECTS OF OMEGA-3 FATTY ACIDS ON RESTING CEREBRAL PERFUSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIAL	J Prev Alz Dis 2018;5(1):26-30	30
IS A LARGE-SCALE SCREENING FOR ALZHEIMER’S DISEASE POSSIBLE? YES, IN A FEW YEARS	J Prev Alz Dis 2019;6(4):221-222	30
RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2019;6(4):228-231	30
EDITORIAL : MULTI-DOMAIN PREVENTION FOR A MULTI-FACTORIAL DISEASE	J Prev Alz Dis 2014;1(1):4-5	29
THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS	J Prev Alz Dis 2016;3(1):8-12	29
PHYSICAL ACTIVITY AND ß-AMYLOID BRAIN LEVELS IN HUMANS: A SYSTEMATIC REVIEW	J Prev Alz Dis 2015;2(1):56-63	28
COMMENT : A NEW ERA: DISEASE MODIFYING ALZHEIMER DISEASE PREVENTION TRIALS	J Prev Alz Dis 2014;1(2):68	28
STUDIES OF AGITATION / AGGRESSION IN ALZHEIMER’S DISEASE – SCIENTIFIC AND OPERATIONAL CHALLENGES	J Prev Alz Dis 2015;2(3):157-159	28
DIETARY FACTORS AND COGNITIVE DECLINE	J Prev Alz Dis 2016;3(1):53-64	28
LESSONS TO BE LEARNED ABOUT CLINICAL TRIALS IN PRECLINICAL AD FROM ONGOING LONGITUDINAL STUDIES	J Prev Alz Dis 2015;2(4):214-215	28
PREVENTION OF ALZHEIMER’S DISEASE IN CHINESE POPULATIONS: STATUS, CHALLENGES AND DIRECTIONS	J Prev Alz Dis 2018;5(2):90-94	28
MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASE	J Prev Alz Dis 2018;5(2):110-119	28
A LITERATURE REVIEW OF METHODOLOGIES USED IN RANDOMIZED CLINICAL TRIALS OF AGITATION IN ALZHEIMER’S DISEASE	J Prev Alz Dis 2018;5(2):120-133	28
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED	J Prev Alz Dis 2014;1(1):8-10	27
BLOOD-BRAIN BARRIER PERMEABILITY IN AGING AND ALZHEIMER’S DISEASE	J Prev Alz Dis 2014;1(3):138-140	27
AMYLOID AND TAU BIOMARKERS IN CSF	J Prev Alz Dis 2015;2(1):46-50	27
INVESTIGATING FUNCTIONAL IMPAIRMENT IN PRECLINICAL ALZHEIMER’S DISEASE	J Prev Alz Dis 2015;2(1):4-6	27
MRI FOR PRE-DEMENTIA TRIALS	J Prev Alz Dis 2016;3(1):5-7	27
DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER’S DISEASE	J Prev Alz Dis 2018;5(2):149-154	26
CLINICAL APPLICATION OF APOE IN ALZHEIMER’S PREVENTION: A PRECISION MEDICINE APPROACH	J Prev Alz Dis 2018;5(4):245-252	26
LONGITUDINAL COMPARISON OF IN CLINIC AND AT HOME ADMINISTRATION OF THE COGSTATE BRIEF BATTERY AND DEMONSTRATED PRACTICE EFFECTS IN THE MAYO CLINIC STUDY OF AGING	J Prev Alz Dis 2020;7(1):21-28	26
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED?	J Prev Alz Dis 2014;1(1):6-7	25
BASELINE SUBJECTIVE MEMORY COMPLAINTS ASSOCIATE WITH INCREASED RISK OF INCIDENT DEMENTIA: THE PREADVISE TRIAL	J Prev Alz Dis 2015;2(1):11-16	25
IMMUNOTHERAPY OF AD: ALUM DEMAIN?	J Prev Alz Dis 2015;2(2):80-81	25
COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIES	J Prev Alz Dis 2017;4(1):3-11	25
REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH	J Prev Alz Dis 2019;6(1):2-15	25
FACTORS ASSOCIATED WITH ALZHEIMER’S DISEASE: AN OVERVIEW OF REVIEWS	J Prev Alz Dis 2019;6(2):121-134	25
IMPACT OF DIETARY FACTORS AND INFLAMMATION ON COGNITION AMONG OLDER ADULTS	J Prev Alz Dis 2015;2(4):220-226	24
NEW IPA CRITERIA FOR AGITATION IN COGNITIVE IMPAIRMENT	J Prev Alz Dis 2015;2(3):160-162	24
BARRIERS FOR PREVENTION AND PRODROMAL AD TRIALS	J Prev Alz Dis 2016;3(2):66-67	24
TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASE	J Prev Alz Dis 2018;5(3):160-164	24
WEB-BASED SOFTWARE FOR REAL-TIME SIMULATION-ASSISTED TRIAL DESIGN IN ALZHEIMER’S DISEASE	J Prev Alz Dis 2016;3(1):20-23	23
TEA FOR ALZHEIMER PREVENTION	J Prev Alz Dis 2015;2(2):136-141	23
SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMES	J Prev Alz Dis 2016;3(1):13-19	23
THE VALUE OF PRE-SCREENING IN THE ALZHEIMER’S PREVENTION INITIATIVE (API) AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE TRIAL	J Prev Alz Dis 2018;5(1):49-54	23
ALZHEIMER’S PREVENTION EDUCATION: IF WE BUILD IT, WILL THEY COME? www.AlzU.org	J Prev Alz Dis 2014;1(2):91-98	22
COMMENT : ALZHEIMER’S DISEASE DRUG DEVELOPMENT: TRIAL-READY COHORTS SHOULD HELP	J Prev Alz Dis 2014;1(2):69-70	22
ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA?	J Prev Alz Dis 2014;1(3):141-142	22
FOREWORD: AD DRUG DEVELOPMENT IS NOT BROKEN: CLINICAL TRIALS IN ALZHEIMER’S DISEASE 2014 CONFERENCE, PHILADELPHIA	J Prev Alz Dis 2014;1(3):212-213	22
COGNITIVE REHABILITATION IN ALZHEIMER’S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEW	J Prev Alz Dis 2015;2(2):142-152	22
DEMENTIA PREVENTION BY DISEASE-MODIFICATION THROUGH NUTRITION	J Prev Alz Dis 2017;4(3):138-139	22
A NOVEL STUDY PARADIGM FOR LONG-TERM PREVENTION TRIALS IN ALZHEIMER DISEASE: THE PLACEBO GROUP SIMULATION APPROACH (PGSA). APPLICATION TO MCI DATA FROM THE NACC DATABASE	J Prev Alz Dis 2014;1(2):99-109	21
DEMENTIA PREVENTION: OPTIMIZING THE USE OF OBSERVATIONAL DATA FOR PERSONAL, CLINICAL, AND PUBLIC HEALTH DECISION-MAKING	J Prev Alz Dis 2014;1(2):117-123	21
COMMUNITY-BASED INTERVENTION FOR PREVENTION OF DEMENTIA IN JAPAN	J Prev Alz Dis 2015;2(1):71-76	21
THE HARVARD AUTOMATED PHONE TASK: NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING TESTS FOR EARLY ALZHEIMER’S DISEASE	J Prev Alz Dis 2015;2(4):242-253	21
ALZHEIMER’S ASSOCIATION: INITIATIVES & PUBLIC HEALTH PERSPECTIVE	J Prev Alz Dis 2016;3(4):178-180	21
ALBUMIN, HEMOGLOBIN, AND THE TRAJECTORY OF COGNITIVE FUNCTION IN COMMUNITY-DWELLING OLDER JAPANESE: A 13-YEAR LONGITUDINAL STUDY	J Prev Alz Dis 2017;4(2):93-99	21
ADHERENCE TO THE MEDITERRANEAN DIET IS NOT RELATED TO BETA-AMYLOID DEPOSITION: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECT	J Prev Alz Dis 2018;5(2):137-141	21
PTI-125 REDUCES BIOMARKERS OF ALZHEIMER’S DISEASE IN PATIENTS	J Prev Alz Dis 2020;4(7):256-264	21
COMMENT : E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS FOR STUDY	J Prev Alz Dis 2014;1(2):66-67	20
A PATIENT-CENTERED ANALYSIS OF ENROLLMENT AND RETENTION IN A RANDOMIZED BEHAVIORAL TRIAL OF TWO COGNITIVE REHABILITATION INTERVENTIONS FOR MILD COGNITIVE IMPAIRMENT	J Prev Alz Dis 2014;1(3):143-150	20
ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT)	J Prev Alz Dis 2015;2(2):121-127	20
GINKGO BILOBA EXTRACT CONSUMPTION AND LONG-TERM OCCURRENCE OF DEATH AND DEMENTIA	J Prev Alz Dis 2017;4(1):16-20	20
PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMER’S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDY	J Prev Alz Dis 2019;6(1):34-41	20
ARIZONA ALZHEIMER’S REGISTRY: STRATEGY AND OUTCOMES OF A STATEWIDE RESEARCH RECRUITMENT REGISTRY	J Prev Alz Dis 2014;1(2):74-79	19
AN OPEN-LABEL TRIAL OF YOKUKANSAN ON SLEEP DISTURBANCE IN ALZHEIMER’S DISEASE AND OTHER DEMENTIA	J Prev Alz Dis 2015;2(3):172-177	19
COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER’S DISEASE IN ITALY: RESULTS FROM AN OBSERVATIONAL STUDY	J Prev Alz Dis 2018;5(1):55-64	19
AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENT	J Prev Alz Dis 2019;6(1):63-69	19
THINKING ABOUT COGNITIVE FRAILTY	J Prev Alz Dis 2015;2(1):7-10	18
A NOVEL EIGENVECTOR-BASED METHOD TO DETECT MILD ALZHEIMER’S DISEASE USING EVENT-RELATED POTENTIALS	J Prev Alz Dis 2016;3(2):101-104	18
PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A LONGITUDINAL STUDY	J Prev Alz Dis 2018;5(4):236-244	18
DESIGNING TRIALS OF DISEASE MODIFYING AGENTS FOR EARLY AND PRECLINICAL ALZHEIMER’S DISEASE INTERVENTION: WHAT EVIDENCE IS MEANINGFUL TO PATIENTS, PROVIDERS, AND PAYERS?	J Prev Alz Dis 2019;6(1):20-26	18
COMMENT: HIGH ALZHEIMER’S DISEASE STUDY COMPLEXITY - LOW SUCCESS RATE	J Prev Alz Dis 2014;1(1):11-12	17
CEREAL INTAKE INCREASES AND DAIRY PRODUCTS DECREASE RISK OF COGNITIVE DECLINE AMONG ELDERLY FEMALE JAPANESE	J Prev Alz Dis 2014;1(3):160-167	17
THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ON	J Prev Alz Dis 2014;1(3):176-180	17
NEUROPSYCHOLOGICAL PROFILE OF “COGNITIVE FRAILTY” SUBJECTS IN MAPT STUDY	J Prev Alz Dis 2016;3(3):151-159	17
THE PARADOX OF RESEARCH ON DEMENTIA-ALZHEIMER’S DISEASE	J Prev Alz Dis 2016;3(4):189-191	17
SWINGS AND ROUNDABOUTS IN CNS DRUG BIOMARKERS	J Prev Alz Dis 2017;4(3):134-135	17
BRAIN DONATION BY PROXY: ARE THERE PREDICTORS IN NEURODEGENERATIVE DEMENTIA?	J Prev Alz Dis 2014;1(3):151-159	16
INTEGRATING INFORMATION FROM FDG - AND AMYLOID PET FOR DETECTING DIFFERENT TYPES OF DEMENTIA IN OLDER PERSONS. A CASE-SERIES STUDY	J Prev Alz Dis 2016;3(3):127-132	16
FEMALE SEX AND ALZHEIMER’S RISK: THE MENOPAUSE CONNECTION	J Prev Alz Dis 2018;5(4):225-230	16
REPORT FROM THE FIRST CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) ASIA-CHINA 2018 : BRINGING TOGETHER GLOBAL LEADERS	J Prev Alz Dis 2019;6(2):144-147	16
DIETARY FAT INTAKE AND COGNITIVE FUNCTION AMONG OLDER POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS	J Prev Alz Dis 2019;6(3):204-211	16
COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE SUBSCALE: A VALIDATION STUDY	J Prev Alz Dis 2019;6(4):237-241	16
COMMENT : CLINICAL TRIALS FOR ALZHEIMER’S DISEASE TURNED A CORNER IN 2013’	J Prev Alz Dis 2014;1(2):71-73	15
CLINICAL EFFECTS OF ORAL TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION	J Prev Alz Dis 2017;4(3):136-137	15
AURAPTENE IN THE PEELS OF CITRUS KAWACHIENSIS (KAWACHIBANKAN) CONTRIBUTES TO THE PRESERVATION OF COGNITIVE FUNCTION: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS	J Prev Alz Dis 2018;5(3):197-201	15
DIABETES MELLITUS AND COGNITIVE DECLINE – PREVENTION SHOULD NOT BE DELAYED!	J Prev Alz Dis 2018;5(2):95-97	15
FEASIBILITY OF USING A WEARABLE BIOSENSOR DEVICE IN PATIENTS AT RISK FOR ALZHEIMER’S DISEASE DEMENTIA	J Prev Alz Dis 2020;7(2):104-111	15
MEDITERRANEAN DIET AND MAGNETIC RESONANCE IMAGING-ASSESSED BRAIN ATROPHY IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2014;1(1):23-32	14
HIPPOCAMPAL ASTROCYTES AND ALZHEIMER’S DISEASE	J Prev Alz Dis 2014;1(2):124-128	14
JPAD IS MOVING FAST	J Prev Alz Dis 2016;3(1):3-4	14
ANTIOXIDANTS IN THE DIET AND COGNITIVE FUNCTION: WHICH ROLE FOR THE MEDITERRANEAN LIFE-STYLE?	J Prev Alz Dis 2017;4(1):58-64	14
EPIGALLOCATECHIN 3-GALLATE AS AN INHIBITOR OF TAU PHOSPHORYLATION AND AGGREGATION: A MOLECULAR AND STRUCTURAL INSIGHT	J Prev Alz Dis 2017;4(4):218-225	14
WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE?	J Prev Alz Dis 2018;5(3):165-167	14
INCREASED FUNCTIONAL CONNECTIVITY AFTER LISTENING TO FAVORED MUSIC IN ADULTS WITH ALZHEIMER DEMENTIA	J Prev Alz Dis 2019;6(1):56-62	14
IMPLEMENTING A MEMORY CLINIC MODEL TO FACILITATE RECRUITMENT INTO EARLY PHASE CLINICAL TRIALS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE	J Prev Alz Dis 2019;6(2):135-138	14
OVERTREATING ALZHEIMER’S DISEASE	J Prev Alz Dis 2021;2(8):234-236	14
PREDICTION OF COGNITIVE DECLINE FOR ENRICHMENT OF ALZHEIMER’S DISEASE CLINICAL TRIALS	J Prev Alz Dis 2022;3(9):400-409	14
HIGHER COGNITIVE PERFORMANCE IS PROSPECTIVELY ASSOCIATED WITH HEALTHY DIETARY CHOICES: THE MAINE SYRACUSE LONGITUDINAL STUDY	J Prev Alz Dis 2015;2(1):24-32	13
DIABETES MITIGATES THE ROLE OF MEMORY COMPLAINT IN PREDICTING DEMENTIA RISK: RESULTS FROM THE PREVENTION OF ALZHEIMER’S DISEASE WITH VITAMIN E AND SELENIUM STUDY	J Prev Alz Dis 2017;4(3):143-148	13
CARE MANAGEMENT TO PROMOTE TREATMENT ADHERENCE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND VASCULAR RISK FACTORS: A DEMONSTRATION PROJECT	J Prev Alz Dis 2018;5(1):36-41	13
COGNITIVE FRAILTY AND INCIDENCE OF DEMENTIA IN OLDER PERSONS	J Prev Alz Dis 2018;5(1):42-48	13
ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER’S DISEASE IN EXPEDITION 3	J Prev Alz Dis 2018;5(3):184-187	13
EFFECTIVENESS OF THE OPEN SCREENING PROGRAMS IN RECRUITING SUBJECTS TO PRODROMAL AND MILD ALZHEIMER’S DISEASE CLINICAL TRIALS	J Prev Alz Dis 2020;4(7):251-255	13
COST-EFFECTIVENESS OF DEMENTIA PREVENTION INTERVENTIONS	J Prev Alz Dis 2021;2(8):210-217	13
MEMORY BROUGHT TO MIND. FIVE-YEAR FOLLOW-UP OF CASE FINDING AND INTERVENTION OF DEMENTIA IN A SWEDISH PRIMARY HEALTH CARE DISTRICT	J Prev Alz Dis 2015;2(1):17-23	12
IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT	J Prev Alz Dis 2015;2(1):64-70	12
THE EFFECT OF VASCULAR NEUROPATHOLOGY ON LATE-LIFE COGNITION: RESULTS FROM THE SMART PROJECT	J Prev Alz Dis 2016;3(2):85-91	12
SHORT-TERM PRACTICE EFFECTS AND AMYLOID DEPOSITION: PROVIDING INFORMATION ABOVE AND BEYOND BASELINE COGNITION	J Prev Alz Dis 2017;4(2):87-92	12
COMBINING GEOSPATIAL ANALYSIS WITH DEMENTIA RISK UTILISING GENERAL PRACTICE DATA: A SYSTEMATIC REVIEW	J Prev Alz Dis 2018;5(1):71-77	12
PROSPECTS FOR EFFECTIVE TREATMENT OF THE DEMENTIA-ALZHEIMER SYNDROME: A RENEWED ODYSSEY IN SEARCH OF THE MAGIC ELIXIR	J Prev Alz Dis 2017;4(4):215-217	12
ASSESSMENT OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT)	J Prev Alz Dis 2018;5(4):216-224	12
BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED	J Prev Alz Dis 2019;6(2):112-120	12
GEROSCIENCE AND THE ROLE OF AGING IN THE ETIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2020;7(1):2-3	12
DATA-DRIVEN PARTICIPANT RECRUITMENT: FINDINGS FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 3	J Prev Alz Dis 2020;7(2):122-127	12
A MACHINE LEARNING FRAMEWORK FOR ASSESSMENT OF COGNITIVE AND FUNCTIONAL IMPAIRMENTS IN ALZHEIMER’S DISEASE: DATA PREPROCESSING AND ANALYSIS	J Prev Alz Dis 2020;7(2):87-94	12
CURRENT STATE OF SELF-ADMINISTERED BRIEF COMPUTERIZED COGNITIVE ASSESSMENTS FOR DETECTION OF COGNITIVE DISORDERS IN OLDER ADULTS: A SYSTEMATIC REVIEW	J Prev Alz Dis 2021;3(8):267-276	12
THE UPS AND DOWNS OF AMYLOID IN ALZHEIMER’S	J Prev Alz Dis 2022;1(9):92-95	12
THE TIMECOURSE OF GLOBAL COGNITIVE GAINS FROM SUPERVISED COMPUTER-ASSISTED COGNITIVE TRAINING: A RANDOMISED, ACTIVE-CONTROLLED TRIAL IN ELDERLY WITH MULTIPLE DEMENTIA RISK FACTORS	J Prev Alz Dis 2014;1(1):33-39	11
THE RELATIONSHIP OF HEMOGLOBIN LEVELS, DELIRIUM AND COGNITIVE STATUS IN HOSPITALIZED GERIATRIC PATIENTS: RESULTS FROM THE CRIME STUDY	J Prev Alz Dis 2015;2(3):178-183	11
NEW FINDINGS WITH REANALYSIS OF THE DOMINO TRIAL ?	J Prev Alz Dis 2015;2(3):212	11
ASSESSING THE RELATIONSHIP BETWEEN VITAMIN D STATUS AND IMPAIRMENTS IN COGNITIVE AND PHYSICAL PERFORMANCE IN OLDER ADULTS USING A DUAL TASK PHYSICAL PERFORMANCE TEST	J Prev Alz Dis 2017;4(1):29-36	11
ASSOCIATIONS OF LONG-TERM TEA CONSUMPTION WITH DEPRESSIVE AND ANXIETY SYMPTOMS IN COMMUNITY-LIVING ELDERLY: FINDINGS FROM THE DIET AND HEALTHY AGING STUDY	J Prev Alz Dis 2018;5(1):21-25	11
EFFECTS OF A SIX-MONTH MULTI-INGREDIENT NUTRITION SUPPLEMENT INTERVENTION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, VITAMIN D, RESVERATROL, AND WHEY PROTEIN ON COGNITIVE FUNCTION IN OLDER ADULTS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL	J Prev Alz Dis 2018;5(3):175-183	11
MEDITERRANEAN-DASH INTERVENTION FOR NEURODEGENERATIVE DELAY (MIND) DIET SLOWS COGNITIVE DECLINE AFTER STROKE	J Prev Alz Dis 2019;6(4):267-273	11
FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS	J Prev Alz Dis 2020;3(7):195-196	11
IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: CURRENT SCENARIO AND FUTURE PERSPECTIVES	J Prev Alz Dis 2021;4(8):534-551	11
STIMULUS-LOCKED LATERALIZED READINESS POTENTIAL AND PERFORMANCE: USEFUL MARKERS FOR DIFFERENTIATING BETWEEN AMNESTIC SUBTYPES OF MILD COGNITIVE IMPAIRMENT	J Prev Alz Dis 2017;4(1):21-28	10
COGNITIVE PERFORMANCE DOES NOT LIMIT PHYSICAL ACTIVITY PARTICIPATION IN THE LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS PILOT STUDY (LIFE-P)	J Prev Alz Dis 2017;4(1):44-50	10
SEX AND AGE DIFFERENCES IN THE ASSOCIATION OF BLOOD PRESSURE AND HYPERTENSION WITH COGNITIVE FUNCTION IN THE ELDERLY: THE RANCHO BERNARDO STUDY	J Prev Alz Dis 2017;4(3):165-173	10
ACTIVITIES OF DAILY LIVING MEASURED BY THE HARVARD AUTOMATED PHONE TASK TRACK WITH COGNITIVE DECLINE OVER TIME IN NON-DEMENTED ELDERLY	J Prev Alz Dis 2017;4(2):81-86	10
DEMENTIA: CREATING A KNOWLEDGE-BASED HEALTHCARE PROFESSION	J Prev Alz Dis 2018;5(1):85-86	10
LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLY	J Prev Alz Dis 2018;5(1):87	10
DETECTION OF RATER ERRORS ON COGNITIVE INSTRUMENTS IN A CLINICAL TRIAL SETTING	J Prev Alz Dis 2018;5(3):188-196	10
BIFIDOBACTERIUM BREVE A1 SUPPLEMENTATION IMPROVED COGNITIVE DECLINE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: AN OPEN-LABEL, SINGLE-ARM STUDY	J Prev Alz Dis 2019;6(1):70-75	10
INTER-SPECIES GLIA DIFFERENCES: IMPLICATIONS FOR SUCCESSFUL TRANSLATION OF TRANSGENIC RODENT ALZHEIMER’S DISEASE MODEL TREATMENT USING BEXAROTENE	J Prev Alz Dis 2014;1(1):46-50	9
CURCUMIN MICELLES IMPROVE MITOCHONDRIAL FUNCTION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2014;1(2):80-83	9
MODERATE, REGULAR ALCOHOL CONSUMPTION IS ASSOCIATED WITH HIGHER COGNITIVE FUNCTION IN OLDER COMMUNITY-DWELLING ADULTS	J Prev Alz Dis 2016;3(2):105-113	9
EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY	J Prev Alz Dis 2016;3(4):188	9
MODEST OVERWEIGHT AND HEALTHY DIETARY HABITS REDUCE RISK OF DEMENTIA: A NATIONWIDE SURVEY IN TAIWAN	J Prev Alz Dis 2017;4(1):37-43	9
OBJECTIVE COGNITIVE IMPAIRMENT AND PROGRESSION TO DEMENTIA IN WOMEN: THE PROSPECTIVE EPIDEMIOLOGICAL RISK FACTOR STUDY	J Prev Alz Dis 2017;4(3):194-200	9
EXPANDING THE TOOLKIT FOR STUDIES OF AGING	J Prev Alz Dis 2017;4(2):69-70	9
FINANCIAL MANAGEMENT SKILLS IN AGING, MCI AND DEMENTIA: CROSS SECTIONAL RELATIONSHIP TO 18F-FLORBETAPIR PET CORTICAL Β-AMYLOID DEPOSITION	J Prev Alz Dis 2019;6(4):274-282	9
LINKING GEROSCIENCE AND INTEGRATED CARE TO REINFORCE PREVENTION	J Prev Alz Dis 2020;7(2):68-69	9
ELEVATED BLOOD HOMOCYSTEINE AND RISK OF ALZHEIMER’S DEMENTIA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON PROSPECTIVE STUDIES	J Prev Alz Dis 2021;3(8):329-334	9
COMMENTARY: FUTURE OF ALZHEIMER’S DISEASE TREATMENT: COMBINATION THERAPY AND PRECISION MEDICINE	J Prev Alz Dis 2023;4(10):743-745	9
REPLY TO THE LETTER TO THE EDITOR: RESPONSE TO CONCERNS RAISED ON MRI SURVEILLANCE AND CLINICAL IMPLICATIONS OF ARIA IN DISEASE MODIFYING TREATMENT	J Prev Alz Dis 2024;1(11):261-262	9
VALIDATION OF AN ULTRA-SENSITIVE METHOD FOR QUANTITATION OF PHOSPHO-TAU 217 (PTAU217) IN HUMAN PLASMA, SERUM, AND CSF USING THE ALZPATH PTAU217 ASSAY ON THE QUANTERIX HD-X PLATFORM	J Prev Alz Dis 2024;5(11):1206-1211	9
EFFECT OF PUNICALAGIN AND RESVERATROL ON METHIONINE SULFOXIDE REDUCTASE: A POSSIBLE PROTECTIVE CONTRIBUTION AGAINST ALZHEIMER DISEASE	J Prev Alz Dis 2015;2(1):33-37	8
GINKGETIN AMELIORATES NEUROPATHOLOGICAL CHANGES IN APP/PS1 TRANSGENICAL MICE MODEL	J Prev Alz Dis 2016;3(1):24-29	8
POTENTIAL UTILITY OF PRACTICE EFFECTS IN PREVENTIVE TRIALS	J Prev Alz Dis 2017;4(3):140-142	8
STRONG RELATIONSHIP BETWEEN MALNUTRITION AND COGNITIVE FRAILTY IN THE SINGAPORE LONGITUDINAL AGEING STUDIES (SLAS-1 AND SLAS-2)	J Prev Alz Dis 2018;5(2):142-148	8
RESPONSES: LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLY	J Prev Alz Dis 2018;5(1):87	8
CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTS	J Prev Alz Dis 2019;6(2):139-143	8
SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER’S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017	J Prev Alz Dis 2019;6(2):108-111	8
NEUROPSYCHOLOGICAL, PSYCHIATRIC, AND FUNCTIONAL CORRELATES OF CLINICAL TRIAL ENROLLMENT	J Prev Alz Dis 2019;6(4):242-247	8
SENSITIVITY OF THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC), PACC5, AND REPEATABLE BATTERY FOR NEUROPSYCHOLOGICAL STATUS (RBANS) TO AMYLOID STATUS IN PRECLINICAL ALZHEIMER’S DISEASE -ATABECESTAT PHASE 2B/3 EARLY CLINICAL TRIAL	J Prev Alz Dis 2022;2(9):255-261	8
EFFECTIVENESS OF PHYSICAL EXERCISE ON ALZHEIMER’S DISEASE. A SYSTEMATIC REVIEW	J Prev Alz Dis 2022;4(9):601-616	8
ASSOCIATIONS OF STAGES OF OBJECTIVE MEMORY IMPAIRMENT WITH CEREBROSPINAL FLUID AND NEUROIMAGING BIOMARKERS OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2023;1(10):112-119	8
FORECASTING THE PREVALENCE OF ALZHEIMER’S DISEASE AT MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA STAGES IN FRANCE IN 2022	J Prev Alz Dis 2023;2(10):259-266	8
INITIAL EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS RECEIVING ADUCANUMAB FOLLOWING ACCELERATED APPROVAL	J Prev Alz Dis 2023;4(10):765-770	8
THE ROOM WHERE IT HAPPENS: CLINICIAN REFLECTIONS ON RETURNING PRECLINICAL ALZHEIMER’S BIOMARKER RESULTS TO RESEARCH PARTICIPANTS	J Prev Alz Dis 2024;1(11):1-6	8
NEUROPROTECTIVE EFFECTS OF A VARIETY OF POMEGRANATE JUICE EXTRACTS (PJE) AGAINST THE EXCITOTOXIN QUINOLINIC ACID IN HUMAN PRIMARY NEURONS	J Prev Alz Dis 2014;1(2):84-90	7
LETTER TO THE EDITOR: PREVENTING DEMENTIA THROUGH COMMUNITY INVOLVEMENT AND ALTRUISTIC BEHAVIORS	J Prev Alz Dis 2018;5(4):259-260	7
GEOGRAPHIC CLUSTERS OF ALZHEIMER’S DISEASE MORTALITY RATES IN THE USA: 2008-2012	J Prev Alz Dis 2018;5(4):231-235	7
MRI CLINICAL RATINGS AND COGNITIVE FUNCTION IN A CROSS-SECTIONAL POPULATION STUDY OF DEMENTIA: THE CACHE COUNTY MEMORY STUDY	J Prev Alz Dis 2019;6(2):100-107	7
SELF-ADMINISTERED COGNITIVE TESTING BY OLDER ADULTS AT-RISK FOR COGNITIVE DECLINE	J Prev Alz Dis 2020;4(7):283-287	7
THE EU/US TASK FORCE’S FUTURE FOR ANTI-AMYLOID TRIALS: FAITES VOS JEUX	J Prev Alz Dis 2020;3(7):199-200	7
NUTRITION TO PREVENT OR TREAT COGNITIVE IMPAIRMENT IN OLDER ADULTS: A GRADE RECOMMENDATION	J Prev Alz Dis 2021;1(8):110-116	7
PROSPECTIVE ASSOCIATIONS BETWEEN PLASMA AMYLOIDBETA 42/40 AND FRAILTY IN COMMUNITY-DWELLING OLDER ADULTS	J Prev Alz Dis 2021;1(8):41-47	7
SUGAR IN BEVERAGE AND THE RISK OF INCIDENT DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A PROSPECTIVE COHORT STUDY	J Prev Alz Dis 2021;2(8):188-193	7
A WEB-BASED MULTIDOMAIN LIFESTYLE INTERVENTION FOR OLDER ADULTS: THE EMIND RANDOMIZED CONTROLLED TRIAL	J Prev Alz Dis 2021;2(8):142-150	7
EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON COGNITIVE IMPAIRMENT AND INFLAMMATION IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMIZED, SINGLE-BLINDED, PLACEBO-CONTROLLED TRIAL	J Prev Alz Dis 2021;3(8):249-256	7
PREVENTION OF ALZHEIMER’S DISEASE AND COGNITIVE DECLINE WITH DIET & LIFESTYLE: PROCEEDINGS OF THE A. G. LEVENTIS FOUNDATION CONFERENCE	J Prev Alz Dis 2023;1(10):137-143	7
PREDICTIVE UTILITY OF PLASMA AMYLOID AND TAU FOR COGNITIVE DECLINE IN COGNITIVELY NORMAL ADULTS	J Prev Alz Dis 2023;2(10):178-185	7
CTAD TASK FORCE PAPER - NEUROPSYCHIATRIC SYMPTOMS IN AD: CLINICAL TRIALS TARGETING MILD BEHAVIORAL IMPAIRMENT: A REPORT FROM THE INTERNATIONAL CTAD TASK FORCE	J Prev Alz Dis 2024;1(11):56-64	7
AGING, SENESCENCE, AND DEMENTIA	J Prev Alz Dis 2022;3(9):523-531	6
THE EFFECTS OF SUBJECTIVE COGNITIVE DECLINE ON APOE GENOTYPE DISCLOSURE IN THE BUTLER HOSPITAL ALZHEIMER’S PREVENTION REGISTRY	J Prev Alz Dis 2023;2(10):152-161	6
A PRAGMATIC, INVESTIGATOR-DRIVEN PROCESS FOR DISCLOSURE OF AMYLOID PET SCAN RESULTS TO ADNI-4 RESEARCH PARTICIPANTS	J Prev Alz Dis 2024;2(11):294-302	6
EFFECTS OF COMPUTERIZED COGNITIVE TRAINING ON GAIT SPEED IN COMMUNITY DWELLING OLDER ADULTS, A PILOT STUDY	J Prev Alz Dis 2016;3(3):145-150	5
DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER’S DISEASE SPECTRUM	J Prev Alz Dis 2020;3(7):179-183	5
AN INDUSTRY PERSPECTIVE: FUTURE OF ANTI-AMYLOID TRIALS	J Prev Alz Dis 2020;3(7):142-143	5
A IS FOR AMYLOID	J Prev Alz Dis 2020;3(7):140-141	5
A JAPANESE MULTICENTER STUDY ON PET AND OTHER BIOMARKERS FOR SUBJECTS WITH POTENTIAL PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE	J Prev Alz Dis 2021;4(8):495-502	5
COHORT-SPECIFIC OPTIMIZATION OF MODELS PREDICTING PRECLINICAL ALZHEIMER’S DISEASE, TO ENHANCE SCREENING PERFORMANCE IN THE MIDDLE OF PRECLINICAL ALZHEIMER’S DISEASE CLINICAL STUDIES	J Prev Alz Dis 2021;4(8):503-512	5
DISEASE BURDEN AND ATTRIBUTABLE RISK FACTORS OF ALZHEIMER’S DISEASE AND DEMENTIA IN CHINA FROM 1990 TO 2019	J Prev Alz Dis 2022;2(9):306-314	5
CLINICAL RESEARCH INVESTIGATING ALZHEIMER’S DISEASE IN CHINA: CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTION	J Prev Alz Dis 2022;3(9):532-541	5
DEMOGRAPHIC ANALYSIS OF INDUSTRY-SPONSORED ALZHEIMER’S DISEASE TRIAL POPULATIONS IN THE UNITED STATES	J Prev Alz Dis 2023;1(10):130-132	5
PHARMACOLOGICAL INVENTIONS FOR ALZHEIMER TREATMENT IN THE UNITED STATES OF AMERICA: A REVISION PATENT FROM 2010 – 2020	J Prev Alz Dis 2023;1(10):50-68	5
MEDICAL JOURNEY OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER’S DISEASE DEMENTIA: A CROSS-SECTIONAL SURVEY OF PATIENTS, CARE PARTNERS, AND NEUROLOGISTS	J Prev Alz Dis 2023;2(10):162-170	5
LONGITUDINAL EXPOSURE–RESPONSE MODELING OF MULTIPLE INDICATORS OF ALZHEIMER’S DISEASE PROGRESSION	J Prev Alz Dis 2023;2(10):212-222	5
SCREENING OVER SPEECH IN UNSELECTED POPULATIONS FOR CLINICAL TRIALS IN AD (PROSPECT-AD): STUDY DESIGN AND PROTOCOL	J Prev Alz Dis 2023;2(10):314-321	5
NEUROINFLAMMATION BIOMARKERS IN THE AT(N) FRAMEWORK ACROSS THE ALZHEIMER’S DISEASE CONTINUUM	J Prev Alz Dis 2023;3(10):401-417	5
LETTER TO THE EDITOR: FIRST EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES – YET WITHOUT IMAGING THAT CAN RULE OUT CEREBRAL INJURY OR MONITOR EFFICACY OF RECOMMENDED MANAGEMENT	J Prev Alz Dis 2024;1(11):259-260	5
CLINICAL CORRELATES OF THE PET-BASED BRAAK STAGING FRAMEWORK IN ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;2(11):414-421	5
EFFECTS OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIAL	J Prev Alz Dis 2020;7(2):112-121	4
SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERS	J Prev Alz Dis 2020;7(1):4-6	4
IS RELUCTANCE TO SHARE ALZHEIMER’S DISEASE BIOMARKER STATUS WITH A STUDY PARTNER A BARRIER TO PRECLINICAL TRIAL RECRUITMENT?	J Prev Alz Dis 2021;1(8):52-58	4
A NOVEL COMPUTERIZED COGNITIVE STRESS TEST TO DETECT MILD COGNITIVE IMPAIRMENT	J Prev Alz Dis 2021;2(8):135-141	4
ENVIRONMENTAL DISTRACTIONS DURING UNSUPERVISED REMOTE DIGITAL COGNITIVE ASSESSMENT	J Prev Alz Dis 2021;3(8):263-266	4
QUANTIFYING RECRUITMENT SOURCE AND PARTICIPANT COMMUNICATION PREFERENCES FOR ALZHEIMER’S DISEASE PREVENTION RESEARCH	J Prev Alz Dis 2021;3(8):299-305	4
PERIPHERAL BLOOD BRCA1 METHYLATION POSITIVELY CORRELATES WITH MAJOR ALZHEIMER’S DISEASE RISK FACTORS	J Prev Alz Dis 2021;4(8):477-482	4
THE ASSOCIATION BETWEEN PEANUT AND PEANUT BUTTER CONSUMPTION AND COGNITIVE FUNCTION AMONG COMMUNITY-DWELLING OLDER ADULTS	J Prev Alz Dis 2021;4(8):436-441	4
RECRUITMENT OF OLDER AFRICAN AMERICANS IN ALZHEIMER’S DISEASE CLINICAL TRIALS USING A COMMUNITY EDUCATION APPROACH	J Prev Alz Dis 2022;4(9):672-678	4
US ADULTS’ LIKELIHOOD TO PARTICIPATE IN DEMENTIA PREVENTION DRUG TRIALS: RESULTS FROM THE NATIONAL POLL ON HEALTHY AGING	J Prev Alz Dis 2023;1(10):34-40	4
FRUCTOSE CONSUMPTION IS ASSOCIATED WITH A HIGHER RISK OF DEMENTIA AND ALZHEIMER’S DISEASE: A PROSPECTIVE COHORT STUDY	J Prev Alz Dis 2023;2(10):186-192	4
EXPECTANCY DOES NOT PREDICT 18-MONTH TREATMENT OUTCOMES WITH COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENT	J Prev Alz Dis 2024;1(11):71-78	4
ADDING THE TOPOGRAPHICAL INFORMATION FROM TAU-PET TO THE A/T/(N) FRAMEWORK: STEPS TOWARDS STAGING AD IN VIVO	J Prev Alz Dis 2023;3(10):381-386	4
REPRODUCTIVE MARKERS IN ALZHEIMER’S DISEASE PROGRESSION: THE FRAMINGHAM HEART STUDY	J Prev Alz Dis 2023;3(10):530-535	4
ASSOCIATION BETWEEN LONGITUDINAL CEREBROSPINAL FLUID ALZHEIMER’S BIOMARKERS AND THE LIFESTYLE FOR BRAIN HEALTH (LIBRA) INDEX: FINDINGS FROM THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA COHORT STUDY (EPAD LCS)	J Prev Alz Dis 2023;3(10):543-550	4
METFORMIN IN THE PREVENTION OF ALZHEIMER’S DISEASE AND ALZHEIMER’S DISEASE RELATED DEMENTIAS	J Prev Alz Dis 2023;4(10):706-717	4
PHASE 1/2A INTRAVENOUS AND SUBCUTANEOUS OLIGOMERSPECIFIC ANTIBODY KHK6640 IN MILD TO MODERATE ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;1(11):65-70	4
POTENTIAL IMPLICATIONS OF SLOWING DISEASE PROGRESSION IN AMYLOID-POSITIVE EARLY ALZHEIMER’S DISEASE: ESTIMATES FROM REAL-WORLD DATA	J Prev Alz Dis 2024;2(11):310-319	4
AT-HOME ADMINISTRATION OF GANTENERUMAB BY CARE PARTNERS TO PEOPLE WITH EARLY ALZHEIMER’S DISEASE: FEASIBILITY, SAFETY AND PHARMACODYNAMIC IMPACT	J Prev Alz Dis 2024;3(11):537-548	4
EVALUATING CAUSAL EFFECTS OF GUT MICROBIOME ON ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;6(11):1843-1848	4
NEUROPROTECTIVE EFFECTS OF GUARANA (PAULLINIA CUPANA MART.) AGAINST VINCRISTINE IN VITRO EXPOSURE	J Prev Alz Dis 2018;5(1):65-70	3
EFFECTS OF RICE WINE LEES ON COGNITIVE FUNCTION IN COMMUNITY-DWELLING PHYSICALLY ACTIVE OLDER ADULTS: A PILOT RANDOMIZED CONTROLLED TRIAL	J Prev Alz Dis 2020;7(2):95-103	3
THE PATIENT IN YOUR ALZHEIMER’S DISEASE STUDY MAY BE IN ANOTHER: DUPLICATION AND DECEPTION IN CLINICAL TRIALS OF ALZHEIMER’S DISEASE	J Prev Alz Dis 2020;7(1):43-46	3
EXPLORING FACTORS THAT CONTRIBUTE TO JOINING AND REGULARLY PRACTICING IN COGNITIVE TRAINING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP QUALITATIVE STUDY	J Prev Alz Dis 2020;7(2):75-81	3
COMMUNICATING PERSONAL RISK PROFILES OF ALZHEIMER’S DISEASE TO OLDER ADULTS: A PILOT TRIAL	J Prev Alz Dis 2022;1(9):144-150	3
REPRESENTATION OF RACIAL AND ETHNIC MINORITY POPULATIONS IN DEMENTIA PREVENTION TRIALS: A SYSTEMATIC REVIEW	J Prev Alz Dis 2022;1(9):113-118	3
KETONE ESTER EFFECTS ON BIOMARKERS OF BRAIN METABOLISM AND COGNITIVE PERFORMANCE IN COGNITIVELY INTACT ADULTS ≥ 55 YEARS OLD. A STUDY PROTOCOL FOR A DOUBLEBLINDED RANDOMIZED CONTROLLED CLINICAL TRIAL	J Prev Alz Dis 2022;1(9):54-66	3
INTERVENTION FOR COGNITIVE RESERVE ENHANCEMENT IN DELAYING THE ONSET OF ALZHEIMER’S SYMPTOMATIC EXPRESSION (INCREASE) STUDY: RESULTS FROM A RANDOMIZED CONTROLLED STUDY OF MEDICATION THERAPY MANAGEMENT TARGETING A DELAY IN PRODROMAL DEMENTIA SYMPTOM PROGRESSION	J Prev Alz Dis 2022;4(9):646-654	3
A HIERARCHICAL BAYESIAN LATENT CLASS MODEL FOR THE DIAGNOSTIC PERFORMANCE OF MINI-MENTAL STATE EXAMINATION AND MONTREAL COGNITIVE ASSESSMENT IN SCREENING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE	J Prev Alz Dis 2022;4(9):589-600	3
LETTER TO THE EDITOR: GENETICALLY DETERMINED ALZHEIMER’S DISEASE IS ASSOCIATED WITH INCREASED RISK OF VARICOSE VEIN: A MENDELIAN RANDOMIZATION STUDY	J Prev Alz Dis 2022;4(9):816-817	3
WHITE MATTER HYPERINTENSITY AS A VASCULAR CONTRIBUTION TO THE AT(N) FRAMEWORK	J Prev Alz Dis 2023;3(10):387-400	3
HIGH INTAKE OF DIETARY CHOLESTEROL DECREASES THE RISK OF ALL-CAUSE DEMENTIA AND AD DEMENTIA: A RESULTS FROM FRAMINGHAM OFFSPRING COHORT	J Prev Alz Dis 2023;4(10):748-755	3
PLASMA OLIGOMER Β-AMYLOID AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN COGNITIVELY NORMAL OLDER ADULTS ACCORDING TO CEREBRAL AMYLOID DEPOSITION	J Prev Alz Dis 2023;4(10):837-846	3
ETHICAL CONSIDERATIONS AT THE INTERSECTION OF SOCIAL MEDIA AND DEMENTIA PREVENTION RESEARCH	J Prev Alz Dis 2024;2(11):274-284	3
ALZHEIMER’S DISEASE BIOMARKER DECISION-MAKING AMONG PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND THEIR CARE PARTNERS	J Prev Alz Dis 2024;2(11):285-293	3
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIALS UNIT (DIAN-TU): TRIAL SATISFACTION AND ATTITUDES TOWARDS FUTURE CLINICAL TRIALS	J Prev Alz Dis 2024;3(11):558-566	3
PREDICTING COGNITIVE DECLINE FOR NON-DEMENTED ADULTS WITH HIGH BURDEN OF TAU PATHOLOGY, INDEPENDENT OF AMYLOID STATUS	J Prev Alz Dis 2024;4(11):908-916	3
DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND DEMENTIA PREVENTION: A SYSTEMATIC REVIEW OF OBSERVATIONAL EVIDENCE IN RHEUMATOID ARTHRITIS	J Prev Alz Dis 2024;5(11):1339-1347	3
META ANALYSIS OF THE CORRELATION BETWEEN PERIODONTAL HEALTH AND COGNITIVE IMPAIRMENT IN THE OLDER POPULATION	J Prev Alz Dis 2024;5(11):1307-1315	3
SEMORINEMAB PHARMACOKINETICS AND THE EFFECT ON PLASMA TOTAL TAU PHARMACODYNAMICS IN CLINICAL STUDIES	J Prev Alz Dis 2024;5(11):1241-1250	3
EFFECTS OF VITAMIN D3 COMBINED WITH FOLIC ACID ON DOMAIN AND SPECIFIC COGNITIVE FUNCTION AMONG PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CLINICAL TRIAL	J Prev Alz Dis 2024;6(11):1626-1633	3
EDITORIAL : ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA?		2
EFFECTS ON COGNITION OF BERRY, POMEGRANATE, GRAPE AND BIOPHENOLS: A GENERAL REVIEW		2
INTEGRATING BIOMARKER OUTCOMES INTO CLINICAL TRIALS FOR ALZHEIMER’S DISEASE IN DOWN SYNDROME	J Prev Alz Dis 2021;1(8):48-51	2
MENTAL COMPONENT SCORE (MCS) FROM HEALTH-RELATED QUALITY OF LIFE PREDICTS INCIDENCE OF DEMENTIA IN U.S. MALES	J Prev Alz Dis 2021;2(8):169-174	2
A SYSTEMATIC REVIEW ON THE FEASIBILITY OF SALIVARY BIOMARKERS FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2021;1(8):84-91	2
EXECUTIVE FUNCTION PREDICTS THE VALIDITY OF SUBJECTIVE MEMORY COMPLAINTS IN OLDER ADULTS BEYOND DEMOGRAPHIC, EMOTIONAL, AND CLINICAL FACTORS	J Prev Alz Dis 2021;2(8):161-168	2
DOES TEA DRINKING PROMOTE HEALTH OF OLDER ADULTS: EVIDENCE FROM THE CHINA HEALTH AND NUTRITION SURVEY	J Prev Alz Dis 2021;2(8):194-198	2
DETERMINANTS OF MEDICAL DIRECT COSTS OF CARE AMONG PATIENTS OF A MEMORY CENTER	J Prev Alz Dis 2021;3(8):351-361	2
MAIL AND TELEPHONE OUTREACH FROM ELECTRONIC HEALTH RECORDS FOR RESEARCH PARTICIPATION ON COGNITIVE HEALTH AND AGING	J Prev Alz Dis 2021;3(8):292-298	2
SENOLYTIC THERAPY TO MODULATE THE PROGRESSION OF ALZHEIMER’S DISEASE (STOMP-AD): A PILOT CLINICAL TRIAL	J Prev Alz Dis 2022;1(9):22-29	2
IS “PRE-PRECLINICAL AD” HELPFUL TO THE EU/US CTAD TASK FORCE?	J Prev Alz Dis 2022;1(9):184	2
ANXIETY AND DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID-Β BURDEN IN COGNITIVELY UNIMPAIRED OLDER ADULTS	J Prev Alz Dis 2022;2(9):286-296	2
EVERYDAY FUNCTIONING AND ENTORHINAL AND INFERIOR TEMPORAL TAU BURDEN IN COGNITIVELY NORMAL OLDER ADULTS	J Prev Alz Dis 2022;4(9):801-808	2
ASSOCIATION OF A MIND DIET WITH BRAIN STRUCTURE AND DEMENTIA IN A FRENCH POPULATION	J Prev Alz Dis 2022;4(9):655-664	2
ALZHEIMER’S DISEASE CLINICAL TRIAL RESEARCH ADAPTATION FOLLOWING COVID-19 PANDEMIC ONSET: NATIONAL SAMPLE OF ALZHEIMER’S CLINICAL TRIAL CONSORTIUM SITES	J Prev Alz Dis 2022;4(9):665-671	2
AGE, SEX, HYPERTENSIONANDHDL-CALTERSERUMBACE1ACTIVITY IN COGNITIVELY NORMAL SUBJECTS: IMPLICATIONS FOR ALZHEIMER’S DISEASE	J Prev Alz Dis 2022;4(9):708-714	2
PROGRAMMED DEATH OF MICROGLIA IN ALZHEIMER’S DISEASE: AUTOPHAGY, FERROPTOSIS, AND PYROPTOSIS	J Prev Alz Dis 2023;1(10):95-103	2
RISK ESTIMATES OF DEMENTIA AND ALZHEIMER’S DISEASE AMONG DIFFERENT WHOLE GRAIN FOOD CONSUMPTION CATEGORIES: A PILOT STUDY	J Prev Alz Dis 2023;1(10):133-136	2
MEDICAL AND PSYCHIATRIC RISK FACTORS FOR DEMENTIA IN VETERANS WITH AND WITHOUT TRAUMATIC BRAIN INJURY (TBI): A NATIONWIDE COHORT STUDY	J Prev Alz Dis 2023;2(10):244-250	2
A GENETIC VALIDATION OF THE NEURODEGENERATION BIOMARKERS TAU-A AND TAU-C - A MENDELIAN RANDOMIZATION STUDY	J Prev Alz Dis 2023;3(10):536-542	2
GENOTYPIC EFFECTS OF THE TOMM40’523 VARIANT AND APOE ON LONGITUDINAL COGNITIVE CHANGE OVER 4 YEARS: THE TOMMORROW STUDY	J Prev Alz Dis 2023;4(10):886-894	2
RELATIONSHIPS OF HYPNOTICS WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE: A LONGITUDINAL STUDY AND META-ANALYSIS	J Prev Alz Dis 2024;1(11):117-129	2
ALZHEIMER’S DISEASE AND AGING ASSOCIATION: IDENTIFICATION AND VALIDATION OF RELATED GENES	J Prev Alz Dis 2024;1(11):196-213	2
THE THERAPEUTIC EFFECTS OF NONINVASIVE BRAIN STIMULATION COMBINED WITH COGNITIVE TRAINING IN ELDERS WITH ALZHEIMER’S DISEASE OR AMNESIC MILD COGNITIVE IMPAIRMENT	J Prev Alz Dis 2024;1(11):222-229	2
ERRATUM TO: CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL	J Prev Alz Dis 2024;1(11):264	2
LETTER TO THE EDITOR: ALZHEIMER’S DISEASE-ASSOCIATED APOE Ε4 FREQUENCIES IN INDIAN POPULATION GENOMES MAY SUGGEST IMPLICATIONS IN LECANEMAB TREATMENT	J Prev Alz Dis 2024;2(11):525-526	2
IMPACT OF DIFFERENTIAL RATES OF DISEASE PROGRESSION IN AMYLOID-POSITIVE EARLY ALZHEIMER’S DISEASE: FINDINGS FROM A LONGITUDINAL COHORT ANALYSIS	J Prev Alz Dis 2024;2(11):320-328	2
EXAMINING THE DIAGNOSTIC ACCURACY OF A NOVEL PERFORMANCE-BASED TEST FOR ALZHEIMER’S DISEASE SCREENING	J Prev Alz Dis 2024;4(11):903-907	2
ASSOCIATION BETWEEN CEREBROSPINAL FLUID STREM2 LEVELS AND DEPRESSION: THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE STUDY	J Prev Alz Dis 2024;4(11):1087-1092	2
LEFT FRONTOPARIETAL CONTROL NETWORK CONNECTIVITY MODERATES THE EFFECT OF AMYLOID ON COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE: THE A4 STUDY	J Prev Alz Dis 2024;4(11):881-888	2
ALZHEIMER’S DISEASE LINKAGE TO REAL-WORLD EVIDENCE (AD-LINE) STUDY: LINKING CLAIMS DATA TO PHASE 3 GRADUATE STUDY OF GANTENERUMAB	J Prev Alz Dis 2024;5(11):1251-1259	2
MULTIDOMAIN INTERVENTION FOR THE REVERSAL OF COGNITIVE FRAILTY USING A PERSONALIZED APPROACH (AGELESS TRIAL): RECRUITMENT AND BASELINE CHARACTERISTICS OF PARTICIPANTS	J Prev Alz Dis 2024;5(11):1291-1306	2
THE CAUSAL RELATIONSHIP BETWEEN GENETICALLY PREDICTED BIOLOGICAL AGING, ALZHEIMER’S DISEASE AND COGNITIVE FUNCTION: A MENDELIAN RANDOMISATION STUDY	J Prev Alz Dis 2024;6(11):1826-1833	2
ASSOCIATIONS OF LATER-LIFE EDUCATION, THE BDNF VAL66MET POLYMORPHISM AND COGNITIVE CHANGE IN OLDER ADULTS	J Prev Alz Dis 2020;7(1):37-42	1
ASSOCIATION OF VITAMIN D LEVELS WITH INCIDENT ALLCAUSE DEMENTIA IN LONGITUDINAL OBSERVATIONAL STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSIS	J Prev Alz Dis 2020;7(1):14-20	1
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA		1
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA		1
KNOWLEDGE, ATTITUDE AND PREVENTIVE PRACTICE ON DEMENTIA CARE AMONG PRIMARY HEALTH PROFESSIONALS IN MACAO	J Prev Alz Dis 2020;7(2):83-86	1
THE EFFECT OF BASELINE PERFORMANCE AND AGE ON COGNITIVE TRAINING IMPROVEMENTS IN OLDER ADULTS: A QUALITATIVE REVIEW	J Prev Alz Dis 2021;1(8):100-109	1
PHYSICAL FITNESS AND APOLIPOPROTEIN E GENOTYPE INFLUENCE CORTICAL NETWORKING AND INTELLIGENCE IN ADOLESCENTS	J Prev Alz Dis 2021;1(8):92-99	1
COMPARATIVE EFFECTIVENESS OF BEHAVIORAL INTERVENTIONS TO PREVENT OR DELAY DEMENTIA: ONEYEAR PARTNER OUTCOMES	J Prev Alz Dis 2021;1(8):33-40	1
MOLECULAR SUBTYPING OF MILD COGNITIVE IMPAIRMENT BASED ON GENETIC POLYMORPHISM AND GENE EXPRESSION	J Prev Alz Dis 2021;2(8):224-233	1
CHINESE VERSION OF THE BAYLOR PROFOUND MENTAL STATUS EXAMINATION: A BRIEF STAGING MEASURE FOR PATIENTS WITH SEVERE ALZHEIMER’S DISEASE	J Prev Alz Dis 2021;2(8):175-180	1
CHILDHOOD SECONDHAND SMOKE EXPOSURE AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE IN ADULTHOOD: A PROSPECTIVE COHORT STUDY	J Prev Alz Dis 2021;3(8):345-350	1
DETERMINANTS OF POST-OPERATIVE COGNITIVE DECLINE IN ELDERLY PEOPLE	J Prev Alz Dis 2021;3(8):322-328	1
DEVELOPMENT, VALIDATION AND FIELD EVALUATION OF THE SINGAPORE LONGITUDINAL AGEING STUDY (SLAS) RISK INDEX FOR PREDICTION OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA	J Prev Alz Dis 2021;3(8):335-344	1
ASSOCIATION OF SUBJECTIVE COGNITIVE DECLINE WITH RISK OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE LONGITUDINAL STUDIES	J Prev Alz Dis 2021;3(8):277-285	1
A FAY-HERRIOT MODEL FOR ESTIMATING SUBJECTIVE COGNITIVE DECLINE AMONG MILITARY VETERANS	J Prev Alz Dis 2021;4(8):457-461	1
EARLY-ONSET SUBGROUP OF TYPE 2 DIABETES AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A COHORT STUDY	J Prev Alz Dis 2021;4(8):442-447	1
DIVERSIFYING RECRUITMENT REGISTRIES: CONSIDERING NEIGHBORHOOD HEALTH METRICS	J Prev Alz Dis 2022;1(9):119-125	1
EVALUATION OF MEMANTINE IN AAV-AD RAT: A MODEL OF LATEONSET ALZHEIMER’S DISEASE PREDEMENTIA	J Prev Alz Dis 2022;2(9):338-347	1
THE SINGAPORE GERIATRIC INTERVENTION STUDY TO REDUCE COGNITIVE DECLINE AND PHYSICAL FRAILTY (SINGER): STUDY DESIGN AND PROTOCOL	J Prev Alz Dis 2022;1(9):40-48	1
AT A GLANCE: AN UPDATE ON NEUROIMAGING AND RETINAL IMAGING IN ALZHEIMER’S DISEASE AND RELATED RESEARCH	J Prev Alz Dis 2022;1(9):67-76	1
STUDY PROTOCOL OF A COMPREHENSIVE ACTIVITY PROMOTION	J Prev Alz Dis 2022;2(9):376-384	1
CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATS	J Prev Alz Dis 2022;3(9):480-490	1
INCREASED INCIDENT ALZHEIMER’S DISEASE AMONG INDIVIDUALS WITH VARICOSE VEINS: A POPULATION-BASED COHORT STUDY	J Prev Alz Dis 2022;3(9):441-448	1
SUBJECTIVE COGNITIVE DECLINE IN A REGISTRY SAMPLE: RELATION TO PSYCHIATRIC HISTORY, LONELINESS, AND PERSONALITY	J Prev Alz Dis 2022;3(9):435-440	1
EFFECTS OF NON-INVASIVE BRAIN STIMULATION ON ALZHEIMER’S DISEASE	J Prev Alz Dis 2022;3(9):410-424	1
LETTER TO THE EDITOR: EARLY-ONSET TYPE 2 DIABETES AND RISK OF DEMENTIA	J Prev Alz Dis 2022;3(9):561	1
ALZHEIMER\'S DISEASE PREVENTION HEALTH COACHING	J Prev Alz Dis 2022;2(9):277-285	1
SALIVARY ALPHA-AMYLASE ACTIVITY AND MILD COGNITIVE IMPAIRMENT AMONG JAPANESE OLDER ADULTS: THE TOON HEALTH STUDY	J Prev Alz Dis 2022;4(9):752-757	1
VALIDATION OF THE SAINT LOUIS UNIVERSITY QUALITY OF LIFE QUESTIONNAIRE IN OLDER ADULTS WITH ALZHEIMER’S DISEASE	J Prev Alz Dis 2022;4(9):809-812	1
OBESITY AND BRAIN HEALTH: THE IMPACT OF METABOLIC SYNDROME AND CARDIORESPIRATORY FITNESS ON COGNITIVE PERFORMANCES IN MIDDLE-AGED OBESE WOMEN	J Prev Alz Dis 2022;4(9):701-707	1
ASSOCIATION OF PREECLAMPSIA WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE AMONG WOMEN IN THE FRAMINGHAM OFFSPRING STUDY	J Prev Alz Dis 2022;4(9):725-730	1
OBJECTIVE AND SUBJECTIVE MEASUREMENTS OF MOTOR FUNCTION: RESULTS FROM THE HELIAD STUDY	J Prev Alz Dis 2022;4(9):743-751	1
SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ICAPAMESPIB, A SELECTIVE EPICHAPEROME INHIBITOR, IN HEALTHY ADULTS	J Prev Alz Dis 2022;4(9):635-645	1
DELAYED DECLINE OF COGNITIVE FUNCTION BY ANTIHYPERTENSIVE AGENTS: A COHORT STUDY LINKED WITH GENOTYPE DATA	J Prev Alz Dis 2022;4(9):679-691	1
SOCIOECONOMIC STATUS AND RISKS OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 39 PROSPECTIVE STUDIES	J Prev Alz Dis 2023;1(10):83-94	1
AGE- AND SEX-DIFFERENT ASSOCIATIONS BETWEEN COGNITIVE PERFORMANCE AND INFLAMMATORY BIOMARKERS IN COMMUNITY DWELLING OLDER ADULTS: TOWARDS PRECISION PREVENTIVE STRATEGIES	J Prev Alz Dis 2023;1(10):104-111	1
EMBRYO SELECTION FOR A CARRIER OF AN EARLY-ONSET ALZHEIMER’S DISEASE-ASSOCIATED MUTATION IN THE PSEN1 GENE	J Prev Alz Dis 2023;1(10):144-147	1
ERRATUM TO: CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATS	J Prev Alz Dis 2023;1(10):150	1
ERRATUM TO: ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASE	J Prev Alz Dis 2023;1(10):151	1
SUBJECTIVE COGNITIVE COMPLAINTS: COMPARING THE RELATION BETWEEN SELF-REPORTED VERSUS INFORMANTREPORTED SUBJECTIVE COGNITIVE COMPLAINTS AND COGNITIVE PERFORMANCES IN COGNITIVELY UNIMPAIRED, MILD COGNITIVE IMPAIRMENT AND POPULATIONS WITH DEMENTIA	J Prev Alz Dis 2023;3(10):562-570	1
LIFESTYLE AND SOCIOECONOMIC TRANSITION AND HEALTH CONSEQUENCES OF ALZHEIMER’S DISEASE AND OTHER DEMENTIAS IN GLOBAL, FROM 1990 TO 2019	J Prev Alz Dis 2024;1(11):88-96	1
ASSOCIATION OF LONELINESS WITH COGNITIVE FUNCTIONS	J Prev Alz Dis 2023;4(10):903-908	1
ADULT RENAL DYSFUNCTION AND RISK OF DEMENTIA OR COGNITIVE DECLINE: BRAIN-KIDNEY AXIS HYPOTHESIS BASED ON A SYSTEMATIC REVIEW AND META-ANALYSIS	J Prev Alz Dis 2023;3(10):443-452	1
USEFULNESS OF COMMUNITY PHARMACY FOR EARLY DETECTION OF COGNITIVE IMPAIRMENT IN OLDER PEOPLE USING THE IQCODE QUESTIONNAIRE	J Prev Alz Dis 2023;3(10):488-496	1
TEN YEARS AFTER THE NATIONAL ALZHEIMER’S PLAN: DEMENTIA REMAINS A HIDDEN SYNDROME IN FRANCE	J Prev Alz Dis 2023;3(10):600-606	1
HIGH-FAT DIET-INDUCED DIABETIC CONDITIONS EXACERBATE COGNITIVE IMPAIRMENT IN A MOUSE MODEL OF ALZHEIMER’S DISEASE VIA A SPECIFIC TAU PHOSPHORYLATION PATTERN	J Prev Alz Dis 2024;1(11):138-148	1
A RANDOMIZED PROSPECTIVE SURVEY TARGETING KNOWLEDGE, BARRIERS, FACILITATORS AND READINESS TO PARTICIPATION IN DEMENTIA RESEARCH	J Prev Alz Dis 2023;4(10):790-799	1
SOCIAL DETERMINANTS OF HEALTH AMONG OLDER ADULTS WITH DEMENTIA IN URBAN AND RURAL AREAS	J Prev Alz Dis 2023;4(10):895-902	1
INVESTIGATING THE FACTOR STRUCTURE OF THE PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE AND COGNITIVE FUNCTION INDEX ACROSS RACIAL/ETHNIC, SEX, AND AΒ STATUS GROUPS IN THE A4 STUDY	J Prev Alz Dis 2024;1(11):48-55	1
ASSOCIATION OF BALANCE IMPAIRMENT WITH RISK OF INCIDENT DEMENTIA AMONG OLDER ADULTS	J Prev Alz Dis 2024;1(11):130-137	1
THE IMPACT OF TESTOSTERONE ON ALZHEIMER’S DISEASE ARE MEDIATED BY LIPID METABOLISM AND OBESITY: A MENDELIAN RANDOMIZATION STUDY	J Prev Alz Dis 2024;2(11):507-513	1
INTEGRATED BIOINFORMATIC ANALYSIS AND VALIDATION IDENTIFIES IMMUNE MICROENVIRONMENT-RELATED POTENTIAL BIOMARKERS IN ALZHEIMER’S DISEASE	J Prev Alz Dis 2024;2(11):495-506	1
PERSONALIZED COMPUTATIONAL CAUSAL MODELING OF THE ALZHEIMER DISEASE BIOMARKER CASCADE	J Prev Alz Dis 2024;2(11):435-444	1
FRUIT INTAKE AND ALZHEIMER’S DISEASE: RESULTS FROM MENDELIAN RANDOMIZATION	J Prev Alz Dis 2024;2(11):445-452	1
CARDIOVASCULAR RISK SCALES ASSOCIATION WITH CEREBROSPINAL FLUID ALZHEIMER’S DISEASE BIOMARKERS IN CARDIOVASCULAR LOW CARDIOVASCULAR RISK REGIONS	J Prev Alz Dis 2024;2(11):453-462	1
ASSOCIATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS WITH RISK OF ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	J Prev Alz Dis 2024;3(11):721-729	1
POLYGENIC RISK SCORE REVEALS GENETIC HETEROGENEITY OF ALZHEIMER’S DISEASE BETWEEN THE CHINESE AND EUROPEAN POPULATIONS	J Prev Alz Dis 2024;3(11):701-709	1
FISH AND SHELLFISH CONSUMPTION, COGNITIVE HEALTH AND MORTALITY FROM ALZHEIMER’S DISEASE AMONG US ADULTS AGED 60 AND OLDER	J Prev Alz Dis 2024;3(11):632-638	1
SERUM TAU-A AND TAU-C LEVELS AND THEIR ASSOCIATION WITH COGNITIVE IMPAIRMENT AND DEMENTIA PROGRESSION IN A MEMORY CLINIC DERIVED COHORT	J Prev Alz Dis 2024;3(11):730-738	1
MAGNETIC RESONANCE IMAGING-NEGATIVE CEREBRAL AMYLOID ANGIOPATHY: CEREBROSPINAL FLUID AMYLOID-Β42 OVER AMYLOID POSITRON EMISSION TOMOGRAPHY	J Prev Alz Dis 2024;4(11):1041-1046	1
VALUE OF KNOWING: HEALTH-RELATED BEHAVIOR CHANGES FOLLOWING AMYLOID PET RESULTS DISCLOSURE IN MILD COGNITIVE IMPAIRMENT	J Prev Alz Dis 2024;4(11):958-965	1
LONGITUDINAL EVOLUTION OF FINANCIAL CAPACITY AND CEREBRAL TAU AND AMYLOID BURDEN IN OLDER ADULTS WITH NORMAL COGNITION OR MILD COGNITIVE IMPAIRMENT	J Prev Alz Dis 2024;4(11):966-974	1
INTEREST IN AND EXPERIENCE WITH GENETIC TESTING FOR LATE-ONSET MEDICAL CONDITIONS: RESULTS FROM THE NATIONAL POLL ON HEALTHY AGING	J Prev Alz Dis 2024;4(11):1079-1086	1
LETTER TO THE EDITOR: HYPNOTICS AND INCIDENT DEMENTIA: A RISK ASSESSMENT	J Prev Alz Dis 2024;4(11):1177	1
EVALUATING THE PERFORMANCE OF DIFFERENT CRITERIA IN DIAGNOSING AD AND PRECLINICAL AD WITH THE BAYESIAN LATENT CLASS MODEL	J Prev Alz Dis 2024;5(11):1316-1324	1
EVALUATING THE CAUSAL EFFECT OF TYPE 2 DIABETES ON ALZHEIMER’S DISEASE USING LARGE-SCALE GENETIC DATA	J Prev Alz Dis 2024;5(11):1280-1282	1